













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 




Institute for Genetics and Molecular Medicine 
The Role of ISG15 in Cancer 
By Clare Crean 
 
Masters by Research in Genetics and Molecular Medicine 
2016 
University of Edinburgh 










Firstly, I would like to offer my sincerest thanks to my supervisor Ted Hupp who was 
constantly available for support and questions and who gave me excellent guidance and 
advice on my project. Thank you for awarding me this great opportunity to work in your lab 
and for providing me with all the resources necessary for the project.  Thank you also to all 
the members of Ted Hupp’s and Kathryn Ball’s lab for the welcoming me to the lab and for 
























- Interferons and INF regulated genes………………………………………... 11 
- Functions of Free ISG15……………………………………………………. 13 
- ISGylation and Conjugated ISG15………………………………………….. 13 
- ISG15 in Cancer…………………………………………………………….. 16 
- ISG15 in Viruses……………………………………………………………..21 
- The CRISPR – Cas Process…………………………………………………. 22 
- Single Chain Purification…………………………………………………… 25 
Aims……………………………………………………………………………... 29 
Materials and Methods………………………………………………………… 30 
Materials…………………………………………………………………………  30 
- Solutions Used……………………………………………………………… 30 
- Computer Programs Used…………………………………………………... 33 
- Antibodies Used……………………………………………………………...33 
- Laboratory Machine Equipment…………………………………………..... 33 
- Cell Media………………………………………………………………….. 34 
- Kits Used…………………………………………………………………… 34 
- Miscellaneous Reagents and Equipment…………………………………….34 
- ISG15 Gene Transcript………………………………………………………34 
- CRISPR RNAs……………………………………………………………... 35 
- PCR Primers………………………………………………………………....35 
Methods…………………………………………………………………………..36 
- Preparing Cell Lysate………………………………………………………..36 
- Bradford Assay…………………………………………………………...... 36 
- Quantitative Protein Measurements………………………………………… 36 
4	
	
- Running a Western with Cell Lysate…………………………………….36 
- Developing using ECL………………………………………………….. 37 
- PCR Protocols……………………………………………………………37 
- PCR Purification Protocol for Sequencing……………………………… 38 
- Freezing Cells…………………………………………………………… 38 
- Plasmid Design…………………………………………………………. 38 
- Plasmid Digestion………………………………………………………. 38 
- Gel Purification of Digested Plasmid…………………………………… 39 
- Annealing the pairs of Oligos…………………………………………… 39 
- Ligation Reaction…………………………………………………………40 
- Plasmid sequencing……………………………………………………… 40 
- Nano drop…………………………………………………………………41 
- Double Digestions…………………………………………………………41 
- Plasmid Transfection………………………………………………………42 
- Electroporation………………………………………………………….…42 
- FACS Cell Sorting……………………………………………………….. 43 
- Single Chain Purification………………………………………………… 43 
- Elisa Protocol………………………………………………………...……44 
- Dot Blot Protocol………………………………………………………… 45 
Results…………………………………………………………………………46 
- Interferon Induction of the ISG15 Pathway……………………………… 46 
• INFα induction Vs. INFβ induction……………………………………46 
• Timecourse of ISG15 Induction by INFβ………………………………47 
• INFβ induction of ISG15 Conjugation…………………………………48 
• INF Induction of IG15 Pathway Members……………………………..49 
 
- CRISPR CAS Process………………………………………………………50 
• CRISPR Cas RNA targeting Exon 2…………………………………….50 
• CRISPR Cas RNA targeting the C-Terminus and Exon 2………………56 
 
- Single Chain Purification of ISG15…………………………………………60 
• Plasmid Induction Single Chain Protocol A……………………………..60 
5	
	
• Plasmid Induction and Purification of Single Chain Protocol B and C…….62 
• Testing the Affinity of the Purified Single Chain…………………………..63 
Discussion………………………………………………………………………….68 
- Interferon Induction of the ISG15 Pathway……………………………………68 
- CRISPR CAS Process………………………………………………………… 70 
• CRISPR Cas RNA targeting Exon 2……………………………………….70 
• CRISPR Cas RNA targeting the C-Terminus and Exon 2…………………72 
- Single Chain Purification of ISG15……………………………………………73 























Interferon stimulated gene 15 (ISG15) is 165 amino acids in length and its protein is roughly 
15kDa. ISG15 is a member of the ubiquitin-like family (Ubl) and shows homology to several 
regions of ubiquitin. The ISG15 protein was first identified in 1979 in mouse Ehrlich ascites 
tumour cells. ISG15 is upregulated by type 1 interferons, primarily α and β. ISG15 can also be 
induced by IFN regulated factors (IRFs).  
ISG15 has two different forms in a cell. The free form and the conjugated form. The free form 
has been shown to have anti-tumour effects whereas the conjugated form is generally involved 
in tumorigenesis. A higher concentration is found in primary tumours with the levels 
decreasing as the tumour progresses in stages. Therefore, ISG15 could be potentially used as 
an early detection diagnostic marker.  
ISG15 is normally only conjugated to a small number of proteins in a cell. It has been suggested 
that these proteins are localized to a specific functional cellular site or else the modification 
significantly alters the protein. ISGylation is a post-translational modification similar to 
ubiquitination. ISGylation is the process through which ISG15 can be conjugated to a target 
protein. The ISGylation process is thought to antagonize the ubiquitin pathway. Proteins which 
are selected for degradation via the ubiquitin/26S proteasome pathway can be stabilised by 
ISGylation and avoid degradation. If this occurs with proteins which normally exert an 
oncogenic effect, malignant growth can ensue. This is the case with proteins such as k-Ras. 
In this project, three different aspects of ISG15 were investigated; the role of type 1 interferons 
in ISG15 induction, targeted knock-down of ISG15 using CRISPR plasmids and single chain 
purification of ISG15.  
To investigate the IFN induction of ISG15, cells were transfected for varying lengths of time 
and then the expression levels of ISG15 were compared using Western blot analysis. The 
optimum time of INF transfection for ISG15 production is between 16 and 24 hours with no 
difference being seen for transfecting for a longer time period.  
The targeted knock-down of ISG15 using the CRISPR/CAS9 technique showed that the best 
area of the gene to target was the C-terminus as it was the only area to show a physiological 




Following the single chain purification, the activity was tested using Elisas and showed to have 



























BSA – Bovine Serum Albumin 
Cas - CRISPR-associated 
CDK1 - Cyclin-dependent kinase 1 
CDRs - complementary determining regions 
CPT – Camptothecins 
CRISPR - clustered regularly interspaced short palindromic repeats 
crRNA – CRISPR RNA 
DNA – Deoxyribonucleic Acid 
DSB – Double-stranded break 
DTT – Dithiothreitol 
EA - oesophageal adenocarcinoma 
ECL – Enhanced chemiluminescence  
ELISA – Enzyme-Linked Immunosorbent Assay  
ESCC - oesophageal squamous cell carcinoma 
Fab – Fragment Antigen Binding  
Fc- Fragment Crystallisable  
Fv Fragment Variable  
GAPDH - Glyceraldehyde 3-phosphate dehydrogenase 
GFP - green fluorescent protein 
HCV – Hepatitis C Virus 
HF – High Fidelity  
HIV - Human Immunodeficiency Virus 
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Chapter 1:  
Introduction  
Interferon stimulated gene 15 (ISG15) is an interferon-regulated protein. It is 165 amino acids 
in length and is roughly 17kDa.(Tao et al. 2015; Li et al. 2014) (Dao et al. 2006) ISG15 is a 
member of the ubiquitin-like family (Ubl) and shows homology to several regions of ubiquitin. 
(Wood et al. 2012; Desai et al. 2006a) Other UBLs include NEDD8, SUMO1-4 and ATG8 & 
12. The ISG15 protein was first identified in 1979 in mouse Ehrlich ascites tumour cells by 
Farrell and colleagues by using ubiquitin antibodies. (J et al. 2015; Pitha-Rowe & Pitha 2007) 
It was first noted as a ubiquitin cross-reactive protein ISG15 is one of the most highly induced 
ISGs.  
1.1 Interferons and INF regulated genes 
Interferons are divided into 3 categories; type 1 interferons (INFα, β, ω and τ), type 2 
interferons (INFϒ) and type 3 interferons (INFλ). (Jeon et al. 2010) ISG15 is upregulated by 
type 1 interferons, primarily α and β.  
1.1.1Type-1 Interferons 
Type 1 IFNs operate through the activation of the Janus Tyrosine Kinase (JAK)/signal 
transducer and activator of transcription (STAT) signalling pathway. (T. Li et al. 2013; Marotta 
et al. 2011)Interferons are members of the cytokine family and as such the help regulate the 
innate immune response to target infections and tumour cells. (Sainz et al. 2016) Type 1 IFNs 
play a very important role in the innate immune response. (Liu et al. 2004; Katsounas et al. 
2013) They are involved in inhibiting cell cycle progression and promoting programmed cell 
death and so they have been used in leukaemia treatments as well as other cancers. (Kim et al. 
2015)	The release of IFNs signals the start of a signalling pathway that ends in the upregulation 
of interferon-stimulated genes. (Andersen & Hassel 2006)(Liu et al. 2011) 
The presence of interferons has been noted in multiple serious viral infections such as HIV, 
hepatitis and human papillomavirus. (Katsounas et al. 2013) Despite this, hepatitis is the only 
one of these viral condition to utilize type-1 IFNs in treatment options. (Geffin et al. 
2013)There have been mixed reports on the use of Type-1 IFNs in HIV therapy as well as in 




1.1.2 IFN Regulated Factors 
ISG15 can also be induced by IFN regulated factors (IRFs).(Juang et al. 1998) The 55 kDa IRF 
3 protein was the first IRF to be reported. It can be activated by viral infection. (Desai et al. 
2006) (Juang et al. 1998)The ISG15 gene has a 5’-cis-regulatory sequence called the interferon-
stimulated response element (ISRE). Several IRFs such as IRF 3 and IRF 9 can form a bond 
with the ISRE for ISG15 induction.(Desai et al. 2006b; Kim et al. 2015). ISG15 can be induced 
through many pathways however. ISG15 is targeted by NF-κB and by p53. The crucial genes 
regulated by IRF1 were identified by Harman and colleagues through micro-array expression. 
(Harman et al. 2011) 
1.1.3 Interferon- Induced Transmembrane Proteins: 
First identified by Brass and colleagues, interferon-induced transmembrane (IFITM) proteins 
are powerful suppressors of many viral infections such as West Nile virus. It also has the ability 
to suppress HIV-1 replication. (Lu et al. 2011) Members of the IFITM protein family contain 
two transmembrane domains as well as a highly conserved intracellular region. The N-terminus 
and the C-terminus face away from the plasma membrane toward the extracellular 
environment. (Lu et al. 2011)(Liu et al. 2011) IFITM1 is also known as 9-27 or Leu13. IFITM1 
is induced by INFγ which is a downstream member of the ISGylation pathway. IFITM1 is 
stimulated by interferons due to the presence of an interferon stimulation response element 
(ISRE) in their promoters.(Dao et al. 2006) IFITM proteins are involved in cellular mechanisms 
such as cell adhesion, oncogenesis as well as immune response. Tumours can also show 
elevated levels of IFITM proteins. (Lu et al. 2011) (Liu et al. 2011) Despite their important 
role in cellular functions, IFITM1 knockouts do not show embryonic lethality. (Liu et al. 2011) 
Following an infection, type 1 interferons are induced. (Forster 2012) (Dieterich & Relman 
2011) (Katsounas et al. 2013) In cells, this results in an activation of many pathogen-
recognition receptors. (Forster 2012) Interferons are induced by the activation of the IFN 
regulatory factor (IRF) family members. IRFs are stimulated virally and are activated through 
either TLR3 endosomally or through the RIG-1 like helicase family member which is 
cytoplasmically located. (Forster 2012) 
IFITM proteins are encoded by ISGs and display similar antiviral activity. (Lu et al. 2011) 
IFITM proteins display their antiviral activity by obstructing the entry of the virus into the cell. 
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This is due to the fact that IFITM proteins are membrane associated and block viral entry 
through membrane mediated inhibition. (Lu et al. 2011) 
1.2 Functions of Free ISG15  
ISG15 can be present in a cell as free ISG15 or in a conjugated form. (Fan, Miyauchi-Ishida, 
et al. 2015)(Burks et al. 2015) Free ISG15 and conjugated ISG15 exhibit very different effects. 
Free ISG15 stimulates the immune systems and provides anti-viral and anti-tumor protection. 
Conjugated ISG15 utilizes the ISGyalation pathway to bind to substrate proteins. (Burks et al. 
2015; Liu et al. 2004; Desai et al. 2006a) Free ISG15 can be released extracellularly and 
intracellularly. Extracellular ISG15 displays cytokine-like functions, (Jeon et al. 2010) 
Extracellular ISG15 was first identified in 1991 after human lymphocytes and monocytes 
released ISG15 after IFNβ transfection. It stimulates the production of type II IFNs, activate 
NK cells and induce non-major histocompatibility complex-restricted cytolysis of tumour cell 
targets.(Fan, Arimoto, et al. 2015) (Fan et al. 2015) When ISG15 is secreted into the 
extracellular matrix it tends to have an antitumour function by inducing NK cell proliferation 
and migration towards the tumour. (Scagnolari et al. 2016) (Liu et al. 2004) It also induces the 
release of IFNγ from lymphocytes. In ISG15 knockout mice the lack of NK cell migration is 
fatal in embryos. (Scagnolari et al. 2016) As free ISG15 invokes an innate immune response 
its stands to reason that humans with an inherited ISG15 deficiency are more prone to bacterial 
disease than their homozygous counterparts. (Desai 2015) A lack of intracellular ISG15 
disrupts the aggregation of USP18 which is a strong negative regulator of type 1 interferon 
signalling. This causes an augmentation of INFα and INFβ response. (Chinyengetere et al. 
2015a) (Falvey 2016a) A severe increase in INFα and INFβ causes an upregulation of 
extracellular ISG15 and an unnecessary overactive immune response. (Andersen & Hassel 
2006) 
ISG15 in the intracellular matrix activates MHC-Class 1 antigen presentation, from the 
adaptive branch of the immune system. Therefore, both forms ISG15 seem to create a very 
robust defensive system against cancer. (Falvey 2016a) 
1.3: ISGylation and Conjugated ISG15  
ISGylation is a post-translational modification similar to ubiquitination. ISG15 was initially 
named ubiquitin cross-reactive protein as it was binding to the same antibodies as ubiquitin. 
(Andersen & Hassel 2006) ISGylation is the process through which ISG15 can be conjugated 
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to a target protein. ISGylation functions in a similar yet non-identical fashion to ubiquitination. 
(Fan, Arimoto, et al. 2015) 
 
1.2.1 Members of the ISGylation Pathway: 
The sequential action of enzymes E1, E2 and E3 are necessary to transfer ISG15 to its target 
protein. (Desai et al. 2006a) There are a variety of enzymes in the E1, 2 and 3 family. Ubiquitin 
E1-like protein (UBE1L) is the ISG15s activating enzyme. E1 is an ATP-dependent enzyme 
which is responsible for activating the pathway. (Pitha-Rowe & Pitha 2007) (Jeon et al. 2010) 
Ubiquitin-conjugating enzyme E2 (UBE2E) is the conjugating enzyme necessary for 
ISGylation. Interferon-induced transmembrane protein (IFITM1) contains remnants of the 
active site of E2 and so it has been theorised that it expedites the E2 function by creating an 
isopeptide bond between ISG15 and its targeted protein. (Fan et al. 2015) Tripartite motif-
containing 25 (TRIM25) is an example of an E3 ligating enzyme. (Liu et al. 2011) UBE1L can 
form a thioester bond with ISG15 yet it does not with ubiquitin. This indicates that it is specific 
to ISG15 ISGylation. UBE1L’s C-terminal has a ubiquitin fold domain that is necessary for 
the transfer of ISG15 to UbcH8 from UBE1L. (Desai et al. 2008a) 
 





USP18 (UBP43) is an ISG15 regulated enzyme and is involved in the stabilisation of antiviral 
proteins. USP18 is also known to suppress INFα and drug induced programmed cell death by 
binding to IFNAR2 and displacing JAK1. (Li et al. 2014) This supports the theory that some 
ISGylation genes which are involved in antiviral defence can also have chemo-protective 
functions when associated with oncogenesis. (Liu et al. 2004) The effects of ISGylation are 
two-fold; firstly, the direct addition of ISG15 alters the protein, secondly, it antagonizes the 
ubiquitin pathway preventing the degradation. ISG15 is normally only conjugated to a small 
number of proteins in a cell. A question which has often been raised is how such a small 
percentage of ISGylated proteins can have such a significant biological effect. It has been 
suggested that these proteins are localized to a specific functional cellular site or else the 
modification significantly alters the protein. (Desai 2015) 
1.2.2 ISGylation and the Ubiquitin Pathway	
The ISGylation process is thought to antagonize the ubiquitin pathway. Proteins which are 
selected for degradation via the ubiquitin/26S proteasome pathway can be stabilised by 
ISGylation and avoid degradation. (Asher et al. 2005) If this occurs with proteins which 
normally exert an oncogenic effect, malignant growth can ensue. This is the case with proteins 
such as k-Ras. The exact mechanism through which the ISGylation pathway antagonizes has 
not been fully elucidated yet there are several logical theories. It is believed ISGylation may 
disrupt the pathway by monopolising the E1, E2 and E3 enzymes which are needed in both 
processes. The pathways also compete for substrate binding sites. ISG15 binds to substrates 
through its UBL domains thus it binds to the same sites on the target protein as ubiquitin. 
(Wood et al. 2012) Lys 29 is an ISG15 specific binding site on ubiquitin. ISG15 can also bind 
to NEDD8 and SUMO modification site, Lys 48. (Fan et al., 2015). Free ISG15 has the ability 
to bind to NEDD4 and blocks NEDD4 form mediating ubiquitination.(Liu et al. 2004; Wood 
et al. 2012) NEDD8 conjugates to a member of SCF-E3 ubiquitin ligases, Cullins, which 
initiates the enzymatic activity of E3 ligases and aids the conjugation of ubiquitin to its cellular 
targets. (Jeon et al. 2010) A recent report has also put forward a third branch of inhibitory 
functions. A paper by Fan and colleagues in 2015 described a process in which ISG15 actually 
binds to ubiquitin itself forming mixed-chains. ISG15 can bind to ubiquitin, incorporating itself 
into the ubiquitin chains which affects ubiquitin’s ability to degrade targeted proteins. 
Proteasome inhibitors alter the amount of ISGylated proteins within a cell. (Desai et al. 2012; 
Desai et al. 2006b) As ISGylation is seen as an antagonist of the ubiquitination process the 
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level of polyubiquitinated proteins decreases as the level of ISGylated proteins increases. 
(Wood et al. 2012) 
When UBE2L6 is silenced in cells, the cell becomes more responsive to chemotherapy and are 
more apoptosis competent. (J et al. 2015)The same results are not seen when ISG15 is 
knockdown using siRNA. This leads us to believe that the apoptotic effect of UBE2L6 is 
separate to the ISGylation pathway. (J et al. 2015; Liu et al. 2004) 
Proteomic investigations have shown that ISG15 itself has the ability to alter ubiquitin. It does 
this by assimilating into ubiquitin chains which has an adverse effect on the degradation of 
ubiquitylated proteins. (Fan, Miyauchi-Ishida, et al. 2015) 
The ISGylation process targets over 300 substrate proteins in human cells. The proteins 
involved in this process include proteins involved in cytoskeleton organization, RNA splicing, 
stress response and translation. (Fan, Miyauchi-Ishida, et al. 2015) Many proteins that form 
parts of an antiviral signalling pathway are targets for ISGylation. (Chinyengetere et al. 2015b) 
In order to understand the role of ISG15 conjugation, one first needs to identify the proteins 
that undergo ISGylation. One of the most valuable tools used for identifying ISG15 conjugated 
proteins is the 293T conjugation system. This method involves ISG15 modifying a small 
amount of the protein in question. This protein can then be detected after affinity enrichment. 
(Desai et al. 2012)  
 
1.3 ISG15 in Cancer: 
ISG15 was first discovered in 1979 yet very little research was completed around that time. 
(Desai et al. 2006a) It was only when ISG15 was seen to be deregulated in cancers that some 
serious investigation was undertaken. From this ISG15 roles such as its antagonizing the 
ubiquitin pathway and its involvement in cell survival were discovered. (Laljee et al. 2013) 
1.3.1 Anti-tumour Effects of ISG15: 
As previously stated ISG15 has two different forms in a cell, the free form and the conjugated 
form. The free form has been shown to have anti-tumour effects whereas the conjugated form 
is generally involved in tumorigenesis. (Desai 2015) 
It is possible that free ISG15 functions differently in different parts of the cell. In the extra 
cellular milieu, it may function to establish antitumour innate immune response by activating 
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NK cells in vivo. (Burks et al. 2015) Intracellular free ISG15 may contribute to activate the 
adaptive arm of the immune system by enhancing MHC-class 1 antigen presentation in vivo. 
Vaccination against free ISG15 results in CD8-mediated reductions in both primary and 
metastatic mammary tumour in mice. (Desai et al. 2012) Tumour cells deregulate the function 
of free ISG15, probably by blocking its secretion by conjugating it to cellular proteins 
consequently, escaping immune surveillance.(Chen et al. 2016) 
Due to its presence in a variety of cancers, ISG15 is quite rapidly becoming used as an 
oncogenic biomarker. (Falvey 2016a) 
1.3.2 Pro-tumour Effects of ISG15: 
ISG15 stabilizes proteins via the ISGylation process. When this process is upregulated, proteins 
which should be degraded escape ubiquitination.(Fan, Miyauchi-Ishida, et al. 2015; Dao et al. 
2006) Ubiquitin maintains the homeostasis of cellular proteins and so when this balance is 
altered aberrant changes begin to happen within the cell. (Desai et al. 2012) ISG15 is known 
to bind to K-Ras and Survivin, both of which are known oncogenes. It has been proposed that 
ISG15 modulates Survivin ubiquitination via XIAP. (Li et al. 2014) The presence of ISG15 
weakens the link between XIAP and Survivin. ISG15 is believed to block XIAP from 
interacting with Survivin which leads to Survivin being stabilized. (Li et al. 2014) (Y. R. Li et 
al. 2013) ISG15 can reduce expression of Cyclin B1 and CDK1 and can induce G2/M phase 
cell cycle arrest. It can also boost tumour cell migration. XIAP functions as an active centre of 
E3 and is responsible for the ubiquitination of substrates. (Li et al. 2014)	
Due to the fact that cancer treatments can increase the level of ISG15 conjugates, ISG15 is 
thought to be a tumour suppressor. However, an overexpression of ISG15 is correlated 
oncogenesis. (Desai et al. 2008b) When conjugated, ISG15 loses its immunological ability. It 
is the disruption of the ISGylation pathway that is associated with tumour progression. 
Increased levels of ISG15 conjugates have been detected in many tumours. A higher 
concentration is found in primary tumours with the levels decreasing as the tumour progresses 
in stages. Therefore, ISG15 could be potentially used as an early detection diagnostic marker. 
(Burks et al. 2015) 
1.3.3 ISG15 and the Cancer Stem Cell Niche: 
The tumour-associated niche of many solid tumours provide information to a subpopulation of 
tumour-initiating cells: cancer stem cells. (Bibikova et al. 2006)(Sancho, Alcala, et al. 
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2016)These stem cells provide the signals and cues necessary for self-renewal and metastatic 
activity. Sainz et al showed in their 2014 paper that ISG15 is found in pancreatic 
adenocarcinoma (PDCA) tumour cells. PDACs secrete INFβ which upregulates ISG15.(Sainz 
et al. 2014) ISG15 in turn creates the stem-like environment that amplifies the oncogenic 
properties of the tumour. This could be due to the stabilizing of proteins that generally increase 
the ‘stemness’ of a cell. K-ras is one of Yamanaka’s key transcription factors which was used 
in his experiment to create iPSCs. (Okita et al. 2007) K-ras is a known oncogene and is also 
one the proteins which is stabilized by ISGylation. ISG15 deficiency suppresses K-ras driven 
lung tumorigenesis and ISGylation of p53 may contribute to tumourigenesis. (Li et al. 2014) 
An ISG15 deficiency silences ki-Ras dependent tumour formation in lung tissue. ISGylation 
bolsters the oncogenic effects of ki-Ras that induces tumorigenesis in vivo. (Zhang et al. 2015) 
1.3.4 Cancer Fieldisation: 
Cancer fieldisation or cancer landscape is a newly discovered phenomenon in cancer research. 
In this process, the tumour and the surrounding tissue have numerous mutations yet something 
triggers the malignant growth in the tumour. (Stransky et al. 2011)(Simple et al. 2015) The 
unusual thing about this phenomenon is that in a lot of cases there is a higher number of 
mutations in the tissue surrounding the tumour than in the actual tumour. This suggests that 
there is a specific mutation in the tumour cells which initiates tumorigenesis. This has been 
seen in squamous tissue cancer of the oesophagus. (Gaykalova et al. 2014) The niche provides 
growth factors and cell signalling cues which promotes the oncogenic nature of the tumour and 
its metastatic ability. (Simple et al. 2015)(Sancho, Alcala, et al. 2016) 
1.3.5 ISG15 in Head and Neck Cancer:	
Head and neck squamous cell cancer (HNSCC) has a significant mortality rate. With 560,000 
new diagnoses a year and 300,000 deaths, it makes up 5% of all tumour patients. The survival 
rate is as low as 50% within 5 years after diagnosis. (McBride et al. 2014) This type of cancer 
is largely related to risk factors such as smoking and high alcohol consumption yet cases can 
occur without partaking in any of these habitual factors. (Stransky et al. 2011a) (McBride et al. 
2014) Despite advances in many other malignancies, treatments for HNSCC have remained 
stagnant over the past few decades. The current treatment is the use of chemotherapy in 
conjunction with intensity-modulated radiation therapy (IMRT). (Gaykalova et al. 2014) Like 
most cancers, HNSCC develops after a build-up of multiple genetic and epigenetic mutations. 
Several distinctive steps occur in this process such as the allelic loss of 9p, 3p, 17p, 11q, 3q, 
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14q, 6p, 8p and 4q. This results multiple mutations in genes such as CDKN2A, TP53 and 
pTEN. (Stransky et al. 2011a) 
Oesophageal cancer is the 8th most common malignancy with a mortality rate of almost 5%. 
(Yan et al. 2012) There are two main histological types; oesophageal adenocarcinoma (EA) 
and oesophageal squamous cell carcinoma (ESCC). In ESCC, surgery is the most common 
form of treatment as it provides the only possibility of a complete cure. It has a 5-year survival 
rate of greater than 95% if the entire tumour is resected in its early stages. (Tao et al. 2015) 
ESCC is difficult to detect in early stages however and so when the cancer is discovered the 
tumour has generally progressed to an advanced stage and the prognosis is poor.(Bektas et al. 
2008) Excessive alcohol consummation is a major risk factor for ESCC and is associated with 
a poor survival rate. A higher expression of ISG15 mRNA was detected in ESCC tissues 
compared with non-tumour tissue samples from the same patient. The expression of ISG15 
mRNA increases as the stages progress so it has been used as a potential marker for a worse 
prognosis. (Tao et al. 2015) (Bektas et al. 2008) 
Oesophageal cancer has one of the worst prognosis of any cancer in the western world. In 
Europe, it has a survival rate of under 15% and is the 8the most common cancer worldwide. 
(Falvey 2016b) ISG15 plays an important role in oesophageal cancers. It is overexpressed in 
roughly 80% of OSCC tissue samples. (Falvey 2016a) Components of the ISGylation pathway 
are upregulated in the cancer cell lines which are apoptosis proficient and show a positive 
response to chemotherapy. (Yan et al. 2012) (Falvey 2016a) ISG15 conjugates to substrates 
that are otherwise soluble. This changes the secretome of the oesophageal tissue creating an 
anti-tumour effect. (Falvey 2016)  
1.3.6 ISG15 in Breast Cancer: 
ISG15 stabilizes key cellular proteins in breast cancer cells. It stabilizes proteins involved in 
cell migration/metastasis conferring increased motility and promotes breast cell 
transformation. Blocking ISG15 or UbcH8 reverses this transformed phenotype.(Marotta et al. 
2011) ISG15 silenced tumours grow rapidly compared to ISG15 overexpressing tumours in 
nude mice. Recombinant free ISG15 inhibits tumour growth when added extracellularly and 
induce intratumour infiltration of NK cells in nude mice. Intracellular free ISG15 enhances 26S 
proteasome-dependent surface expression of MHC class I complex on breast cells. (Burks et 
al. 2015) (Desai et al. 2012) 
ISG15 has been shown to alter focal adhesions and cytoskeletal proteins. (J et al. 2015) 
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Breast cancer cell lines which exhibit invasive tendencies also show higher levels of ISGylated 
proteins. Correspondingly, non-invasive cell lines showed much lower levels of these proteins. 
(J et al. 2015; Burks et al. 2015) ISG15 can play a negative role in breast cancer. As the ISG15 
pathway antagonizes ubiquitination and prevents the degradation of cellular proteins that are 
associated with cell migration. This causes the cancer cells to have increased motility as well 
as promoting breast cell transformation. (J et al. 2015)(Zhang et al. 2015) 
1.3.7 ISG15 in Nasopharyngeal Cancer: 
ISG15 is differentially expressed in nasopharyngeal carcinoma. (Zhou et al. 2015) In NPC 
tissues, elevated amounts of ISG15 corresponds to a shorter overall survival as well as disease-
free survival. This is likely due to the fact that ISG15 overexpression creates a cancer stem cell 
phenotype such as pluripotent gene expression and increased tumorigenesis. (Zhou et al. 2015) 
(Sancho, Barneda, et al. 2016) ISG15 knockdown abated the stem cell characteristics in NPC 
cells. (Sancho, Barneda, et al. 2016) An overexpression of ISG15 in INC cells conferred 
resistance to the chemotherapeutic drug cisplatin as well as to radiation. (Zhou et al. 2015) 
(Chen et al. 2016) For these reasons ISG15 can be used as a prognostic marker for NPC. Work 
is also being carried out to utilise ISG15 as a therapeutic target. (Chen et al. 2016) 
 
1.3.8 ISG15 and Camptothecin: 
Camptothecins (CPT) e.g. topotecan are chemotherapeutic drugs used as a treatment in a 
variety of cancer types. (Liu et al. 2004) Tumours are known to show a varied level of 
resistance to camptothecin. ISG15 was shown to be a determinant for CPT resistance. Knock-
down of ISG15 or UbcH8 resulted in an increased proteasomal degradation of the CPT-induced 
TOP1-DNA covalent complexes. (Desai et al. 2008a) (Desai 2015) CPT destroy tumour cells 
by capturing topoisomerase 1 – DNA covalent complexes. The ubiquitin/26S proteasome 
pathway is induced by CPT which degrades the TOP1-DNA covalent complexes. This 
highlights the importance of the ubiquitin pathway in CPT resistance. (Liu et al. 2004) (Jeon 
et al. 2010)(Jeon et al. 2012)Tumours with high levels of ISG15 will not respond positively to 
camptothecin, therefore treatment of tumours with a high ISG15 content should have tailored 
chemotherapeutic treatment plans. (Desai et al. 2008a)	
IFNs and JAK/STAT are dispensable for camptothecin-mediated induction of ISG15. The 
ISG15 conjugates which are generated by camptothecin are different from the conjugates 
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which are produced by type 1 IFNs. (Wood et al. 2012) Camptothecin significantly increases 
the IFN-induced ISGylation of proteins. Treatment of colorectal cancer in mice with a mixture 
of IFNs and camptothecin shows synergistic cell death. (Desai et al. 2008a)(Liu et al. 2004)	
 
1.4 ISG15 in Viruses: 
ISG15 and its conjugates hinder viral replication in vivo. Congruently some viruses initiate 
viral specific proteins that have the ability to deconjugate ISG15 from its conjugates which 
initiates an antiviral response. (Domingues et al. 2015) In UBE1L -/- mice the ISGylation of 
proteins does not occur. ISG15 -/- mice show no obvious signs of abnormalities and also have 
the ability to reproduce. Nor does a lack of ISG15 affect the cells immune system. (Eduardo-
Correia et al. 2014) INFα and INFβ have been used as clinical drugs since their discovery in 
the mid-20th century. INFα has been used to treat chronic cases hepatitis B and C virus as well 
as certain cancers such as leukaemia. INFβ was shown to be effective at treating multiple 
sclerosis. (Pitha-Rowe & Pitha 2007) (Broering et al. 2016) 
ISGylation has been shown to suppress Ebola through blocking ubiquitin ligase NEDD4. 
Nedd4 is required by viral budding. Although many proteins can be targeted by ISGylation, 
ISG15 tends to target newly synthesized host and viral proteins.(Broering et al. 2016) This 
process allows for localised antiviral activity without the need for widespread protein 
modifications in the cell. (Liu et al. 2011) 
1.4.1 ISG15 and HCV: 
ISG15 has a multitude of functions within the cell. A number of ISGs have been reputed to 
suppress HCV replication. (Katsounas et al. 2013)The exact mechanisms have not been fully 
elucidated yet early reports show the viral replication is blocked by ISG action at several steps 
in the HCV replication cycle. (Pitha-Rowe & Pitha 2007)	The recent literature portraying the 
role of ISG15 in HCV is contradictory yet the popular opinion veers on the side of a proviral 
effect. When ISG15 is overexpressed HCV, replication increases yet when it is silenced it 
inhibits HCV replication to a relatively low extent. (Domingues et al. 2015) 
1.4.2 ISG15 and HIV:	
An induction of ISG15 is seen when the Human Immunodeficiency Virus (HIV) is inhibited 
by type 1 IFNs. (Scagnolari et al. 2016) Moreover, when ISG15 is overexpressed it copies the 
effect of IFN and suppresses the release of HIV-1 virions. In HIV-1 provirus cells, the 
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overexpression of ISG15 and UBE1L completely inhibit HIV replication. (Katsounas et al. 
2013) UBP43 expression however can rescue HIV replication. As the expression of ISG15 
alone fails to block viral replication, it must therefore be the ISGylated proteins and not ISG15 
itself that blocks the viral replication. (Scagnolari et al. 2015; Katsounas et al. 2013) 
Type 1 interferons have multiple capacities with regards to HIV-1 infection. The viral increase 
that is associated with HIV infection results in an augmentation in interferon α due to HIV’s 
ability to counteract the antiviral activity of interferons. (Scagnolari et al. 2015) 
Members of the ISGylation pathway, including ISG15, can activate the production of 
indoleamine 2,3-dioxygenase which controls TNF-related apoptosis-inducing ligand (TRAIL). 
(Harman et al. 2011) These are known to apply immunosuppressive effects on T-cells. The 
debilitated immune system seen in HIV patients is likely due to this mechanism. (Geffin et al. 
2013)  
 
1.5 The CRISPR – Cas Process: 
Type II prokaryotic clustered regularly interspaced short palindromic repeats (CRISPR)/Cas 
adaptive immune system is capable of aiding RNA-guided site specific DNA cleavage. (Cong 
et al. 2013)(Sander & Joung 2014) CRISPR and CRISPR-associated (Cas) proteins are part of 
a bacterial immune system which can detect and kill any invading microorganisms. 
(Domingues et al. 2015) This method has recently been adapted for the generation of 
genetically engineered cells or organisms.  
The CRISPR loci are comprised of an array of repeats that are distanced by ‘spacer’ sequences 
which are identical to the genome of bacteriophages. This repeat-spacer series is transcribed in 
a long precursor and is processed to create short CRISPR RNA that determine the target 
sequences cleaved by CRISPR. (Gaj et al. 2013) Protospacer adjacent motif (PAM) is a 
sequence motif which is directly downstream of the target region and is necessary for cleavage. 
(Cong et al. 2013)  
 
1.5.1 Cas9 Targeting 
Cas 9 nucleases are directed by short RNAs in order to produce a precise cut at a genomic locus 
in eukaryotic cells.(Wang et al. 2013; Sander & Joung 2014) Cas9 may also be changed into a 
nicking enzyme to aid homology-directed repair with the least amount of mutagenesis. (Hwang 
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et al. 2013) The Cas genes generally flank the repeat-spacer series and contain the essential 
enzymatic equipment required for genome targeting. (Wang et al. 2013) Cas9 is comprised of 
a double-stranded DNA endonuclease which utilizes the crRNA guide to determine the 
cleavage site. (Domingues et al. 2015) Cas proteins, CRISPR RNAs and transacting crRNA 
form ribonucleoprotein complexes that target and destroy foreign nucleic acid. This complex 
is guided by the crRNAs. The cas9 endonuclease can be programmed to produce sequence-
specific DSB if a manufactured single-guide RNA containing crRNA and tracrRNA is 
provided. (Jiang et al. 2013) A lot of work has been done to determine the nucleases whose 
sequence specificity is designed by small RNAs. (Jiang et al. 2013) Single-guide RNA 
(sgRNA) is an amalgamation of crRNA and trancrRNA and can direct Cas-9 cleavage of target 
DNA. This cleavage can also be induced by crRNA and trancrRNA functioning together. (Jiang 
et al. 2013) (Sander & Joung 2014) 
1.5.2 Benefits of CRISPR: 
Traditional genome editing techniques have included the use of creating mutations through 
homologous recombination in embryonic stem cells of mice. (Gaj et al. 2013)These cells must 
then be injected into the blastocysts of wild type mice which will then generate chimeric 
offspring. This method is arduous and time consuming and extremely costly to knock-out just 
a single gene. New methods to speed up this process have since been under development. 
(Wang et al. 2013) The DNA of site-specific nucleases can be injected directly into the one-
cell embryo which can generate a double-stranded break at a specific site. The DSB is then 
repaired by error-prone non-homologous end joining (NHEJ). (Wang et al. 2013) (Cong et al. 
2013) Targeted integrations can occur if a donor plasmid with corresponding ends to the DSB 
is coinjected. This requires zinc finger nucleases (ZNF) or transcription activator-like effector 
nucleases TALENs) specific for each gene. The CRISPR-Cas system is an advancement of this 
process. (Gaj et al. 2013) 
The CRISPR Cas system is a much cheaper and less time consuming alternative for genome 
editing. It can quickly and effectively knock down multiple genes in a single cell. In a 2013 
paper written by Wang et al, the authors describe the process of knocking down 5 separate 
genes in a single mouse model simultaneously. This paper shows the dynamic effect of the 
CRISPR Cas system in large scale gene editing. Efficient genetic adaptation is necessary for 
the analysis of disease and development. A CRISPR array can contain several guide sequences 
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that can enable simultaneous editing of several sites. This shows the ease at which the 
mammalian genome can be edited by using CRISPR. (Wang et al. 2013) 
1.5.3 CRISPR Design Process: 
To design CRISPR oligos, programmes such as MIT Optimised CRISPR design program are 
used. This program scans the target genomic region and produces multiple possible designs for 
the short RNA which guides the Cas9 enzyme. The RNA chosen should have the least off-
target sites. The MIT program shows a score out of 100 for each short-RNA with the highest 
score depicting those RNAs which have the fewest off-target sites. An oligo with a score of 
over 90 should be chosen.  
 
Figure 1.2: Sequence map of the plasmid used in the plasmid digestion. 
Image by SnapGene 
 
Once a short-RNA design has been chosen, it must be incorporated into a viral plasmid in order 
to be transfected into the cell. Lentiviruses are often used as they can be economically sourced 
and are easy to manipulate. In the lentiviral plasmid there are two BsmB1 sites which are 1885 
bp apart. Using the BsmB1 restriction enzyme the vector can be cut at these two sites leaving 
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a linear plasmid. A double digestion can be carried out in order to ensure that the plasmid has 
been cut efficiently. The cut vector can be digested with a restriction enzyme for BamH1. If 
the vector has been cut by the BsmB1 restriction enzyme the BamH1 enzyme will bisect the 
cut linear vector and we should get two separate bands. If the BsmB1 restriction enzyme did 
not cut the vector then when the BamH1 restriction enzyme cuts, we should get one linear 
plasmid which would appear as just one band on a gel. Once the linear plasmid has been created 
the short-RNA can be integrated into the plasmid so that the viral plasmid contains the short-
RNA oligo.  
 
1.6 Single Chain Purification: 
 
Antibodies are of great importance in biological research, specifically the antibodies that show 
high specificity and high affinity. Their importance stems from their ability to quantify gene 
expression levels, identify specific loci of gene expression as well as determining interactions 
between the protein and other molecules. (Farajnia et al. 2014)  
1.6.1 Classic Antibodies 
Antibodies are also known by the term immunoglobins (Ig). An IgG is a bivalent, Y-shaped 
antibody. Monoclonal antibodies (Mabs) have some limitations when it comes to biomedical 
research and so antibody fragments were created in order to surpass MAb limitations.(Hoet et 
al. 2005) Previously, these limitations had been overcome by eliminating the Fc region by 
proteolytic treatment with enzymes such as pepsin. General antibodies are comprised of 4 
polypeptide chains two of which are heavy and two of which are light. The light chains contain 
roughly 220 amino acid residues and the heavy chains are approximately double this at 440 
amino acid residues. (Moestrup & Gliemann 1989) (Huston et al. 1993)(Farajnia et al. 2014) 
These chains then fold into domains of roughly 110 amino acids hat form a conserved 3D 
conformation. These domains can then associate into specific structural areas. The antigen 
binding region, also known as the variable region (Whitlow et al. 1993) is created by the 
interaction of the amino termini of the heavy and light chains. (Huston et al. 1988) 
 
 
1.6.2 Single Chain and Peptide Linker Composition 
In recent years the need for more specific antibodies has led to the development of recombinant 
antibodies composed of immunoglobin variable region genes. The most useful of these 
recombinant antibodies is the single-chain Fv antibody.(Malpiedi et al. 2013) ScFv fractions 
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are the smallest VH-VL molecules that are capable of high affinity antigen binding. The single 
chain Fv contains the entire binding site of the antibody in a small, single polypeptide chain. 
The binding site of the scFv can reproduce the affinity and specificity of the original antibody 
combining site. The molecular weight of the polypeptide is roughly 26,000. 
ScFv is comprised of antigen-binding domains of Ig heavy (VH) and light (VL) chain regions 
linked by a flexible peptide. All these components are encoded by a single gene. These single 
chain antibodies are highly useful for in vivo studies where conventional techniques had 
previously failed. (Huston et al. 1993) The VH and VL genes can be obtained from a specific 
hybridoma cell line, taken from a V-gene library or genetically synthesised.  (Smith 1985) 
A single chain is formed when the two V gene components are joined using an oligonucleotide 
which encodes specific linker peptides, Gly-Ser for example. The linker peptide joins the 
beginning of the V region to the N-terminus of the second. (Whitlow et al. 1993) Different 
linker peptides are used for different specificities. Glycine and serine linkers are used for 
flexibility and glutamic acid and lysine charged residues are used for improved solubility. 
Linker peptides are usually between 15 to 20 amino acid residues. (Whitlow et al. 1993) The 
binding site of the antigen is formed by the joining if the two V chains. Within the antigen 
binding domain of immunoglobin there are three hypervariable regions which are known as 
complementary determining regions (CDRs). These form loops and display high sequence 

























1.6.3 Phage Display and Library: 
For the phage display, the antigen-binding segments of VH and VL genes are cloned and used 
to manufacture scFv gene stores. (Sheets et al. 1998) These stores are then cloned as fusion 
proteins with a minor coat protein of bacteriophage to create a phage antibody library. Each 
phage from the library will have an operational antibody protein on its surface. They also 
contain the gene which encodes the antibody. (Casey et al. 1995) Certain phage antibodies that 
bind explicitly to proteins can be sorted apart from phage antibodies that fail to bind through 
affinity chromatography techniques. The quantity and affinity of antibodies created for a 
specific antigen is directly proportional to the size and assortment of the library. This poses 
problems as the production of large libraries has proven difficult. (Casey et al. 1995; Sheets et 
al. 1998) 
The phage display system was first introduced in 1985 when Smith and colleagues displayed 
that foreign DNA fragments can be fused to the gene encoding the phage minor coat protein of 
a bacteriophage and consequently expressed in the form of a fusion protein at the surface of 
the phage without affecting its sensitivity. (Smith 1985) This technique was then utilised by 
professors in Cambridge to produce single chain fragments on the surface of the virion that are 
capable of binding to antigens. (Sheets et al. 1998) 
To select a scFv from phage display libraries, numerous rounds of probing against the antigen 
required is undertaken with washing steps completed inbetween to remove nonspecific phage 
clones. In general, many rounds of probing with increased washing inbetween is needed to 
ensure only high affinity binding phages. (Malpiedi et al. 2013) Using this technique, scientists 
were able to create a high-throughput screening system for phage display that aids antibody 
identification and characterization. (McCafferty et al. 1990) For the single chain purification 
an elution step is needed in order to retrieve the phage molecules that contain the scFv fractions 
which are able to bind to the target protein. Low pH buffers are commonly used in the elution 
phase. (Smith 1985)	
1.6.4 Benefits of Single Chain Antibodies: 
scFvs have many positive qualities. The high stability of the phages allow them to be stored at 
4°C for as long as needed and its production is highly economical as it only requires infecting 
E. coli. (Huston et al. 1988) ScFvs have become increasingly important as forms of cancer 
research and cancer treatments. They possess the ability to recognize specific markers present 
on the cell surface of tumours. The reduced size of the fragments also allows for rapid bio-
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diffusion. (Lillo et al. 2011) The rapid infusion is considerably faster than that of IgG or FAB 
which allows the imaging of isotopes with a short half-life.		 
These single chains can be developed to recognize any antigen required.	They can also be 
designed specifically for certain protein domains as well as for the different epitopes in the 
domains.  Immunological therapies are fast becoming some of the most important treatments 
in cancer therapy. Antibodies can be created to recognize antigens on the surface of tumour 
cells. Examples of this include anti-Her2 scFv and anti-VEGF ScFv. (Chen et al. 1999) The 
Escherichia coli expression system is the most popular choice for recombinant ScFv 
production. (Schmidt et al. 2001) 
Monoclonal antibodies can be ineffective in multiple biological techniques however as 
accidental activation of the effector functions can cause toxicity due to cytokine release. Single 


























The aim of this project was three-fold. First we aimed to investigate the role of type 1 
interferons in the induction of the ISG15 pathway. Secondly we aimed to investigate the knock 
down of ISG15 in cells using the CRISPR Cas system. Lastly we aimed to induce and purify 
and single chain antibody which had a high affinity for ISG15 protein. These aims combined 






















Chapter 2  




10x PBS – 100ml 
ddH20 – 900ml 
Tween – 1ml 
 
Urea Lysis Buffer (2ml) 
 
25mM Hepes pH 7.5 - 50µl 
7M Urea – 840mg 
25mM NaCl - 25µl  
10% Triton x-100 - 10µl 
5mM DTT - 10µl 
ddH20 – 1.905ml  
 
1 M HEPES (1L) pH 7.5 
Disolve 238.3 g HEPES in 800 mL of ddH2O  
Adjust the pH to the desired value with 10 N NaOH   
Bring up the volume to 1 L with ddH2O 
 
50x TAE (1L) 
Dissolve 242.2 g Tris base in around 600 mL of ddH2O  
 Slowly add 57.1 mL glacial acetic acid  
 Add 100 mL 0.5 M EDTA, pH 8  





10x DNA loading buffer (100 mL)  
Measure 20 mL 50x TAE into a 100-mL graduated cylinder  
Add 40 g sucrose  
Add 10 mg bromophenol blue  
Bring up the volume to 100 mL with ddH2O 
 
Ampicillin (1000x) 
Dissolve 5 g ampicillin in 25 mL ddH2O 
Add 25 mL absolute ethanol  
Store at -20 °C 
 
Running Buffer (1L) 10x 
30g Tris  
144g Glycine  
10g of SDS  
1000ml of H2O 
Dilute to 1X before use 
 
 
10x Transfer buffer (4L)  
121.1 g Tris base  
576 g glycine  
Bring up the volume to 4 L with ddH2O 
 
1x Transfer Buffer (1L) 
Methanol – 200ml 
Transfer Buffer 10x – 100ml 
ddH20 -700ml  
 
1M Tris pH 9 (50ml) 
6.6g of Tris  
Dissolve in 40ml of ddH20  
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Bring pH to 9 using drops of HCL  
Bring up to 50ml with ddH20 
 
0.2M Glycine pH2 (50ml) 
0.75g of glycine  
Dissolve in 25ml of ddH20 
Bring pH to 2 using drops of HCL 
Bring up to 50ml with ddH20 
 
PBS-Triton 1% (40ml) 
4ml of PBS 10X 
4ml of 10% Triton x100 
32ml of ddH20 
 
Coomassie Blue Solution (1L) 
Dissolve 1 g of Coomassie Brilliant Blue (Bio-Rad) in 1 litre of the following solution: 
Methanol (50% [v/v]) 
Glacial acetic acid (10% [v/v]) 
H2O (40%) 
Stir the solution for 3-4 hours and then filter through Whatman filter paper. Store at room 
temperature. 
Destaining Solution  
50% ddH2O 
40% Methanol  
10% acetic Acid  
Native Gel  
1.5M Tris pH 8.8 
1.0M Tris 6.8 










Image Studio Lite   
 
Antibodies Used 
Swine Anti-Rabbit 2λ7 
Rabbit Anti-Mouse 260  
GAPDH mAb ab9484 
Abcam Rabbit ISG15 polyclonal Antibody  
Mouse Anti-IRF1 antibody  
Til anti-IFITM1 antibody    
Protein A HRP  
 
Laboratory Machine Equipment: 
Centrifuge 5415R Eppendorf  
Perkin Elmer Lambda Bio  
Soniprep 150 PLUS 
Perkin Elmer Multilable Counter  
Li-Cor Odessey Scanner  
Syngene Bio-Imaging System  
Bio-Rad Power Pack 
Nanodrop 2000c Spectrophotometer  






Cell Media  
Sigma FBS  
Gibco Penicillin Strip 
Gibco RMPI 1640 Media  
Siha Cells – Cervical Cancer Cells  
 
Kits Used: 
Quiagen Gel Extraction Kit  
Quiagen PCR Purification  
Quiagen Miniprep Kit  
Amaxa Cell Line Nucleofactor Kit T 
 
Miscellaneous Reagents and Equipment  
Thermo Scientific PageRuler Plus Prestained Protein Ladder  
Cellulose Nitrate Membrane Filter 
Attractene 
 




























Exon 2 CRISPR RNAs: 
Forward: [Phos]CACCG1AGGCGTGCACGCCGATCTTC  
Reverse: [Phos]AAACGAAGATCGGCGTGCACGCCTC  
                      





PCR Primers  
Short (Original) Primers: 
Forward: GACCTGACGGTGAAGATGCT 
Reverse: GCCCTTGTTATTCCTCACCA 




                 TTCTGGCTGACCTTCGAGGG 
Long Primers: 
Forward: GGCTGAGAGGCAGCGAACTC     
Reverse: GCATCCGAGCAGGATCAAGG 













Preparing Cell Lysate  
Remove all media from plate using the aspirator. Wash three times with 4°C PBS. Add 1ml of 
4°C PBS. Scrape cells using a cell scraper and move to an Eppendorf tube. (All above steps to 
be carried out on ice) Spin for 5 mins at 3000rpm at 4°C. Discard supernatant (Pellets can be 
flash frozen at this point) Resuspend in Xµl of lysate buffer depending on size of pellet. Leave 
on ice for 30 mins. Centrifuge at 13,200rpm for 15 mins. Remove supernatant and place in 
freshly labelled Eppendorf tubes. Test concentration using Bradford reagent. 
Bradford Assay 
1µl of each sample being tested was added to 200µl of Bradford Reagent in a clear microplate. 
1µl of the lysate buffer used was added to 200µl of Bradford Reagent to act as a control. 1µl 
of a titration of BSA standards of known concentrations were also added to 200µl of Bradford 
Reagent. All of these samples are blanked against the cell lysate well. The concentrations of 
the unknown samples are calculated using the known samples are standards.  
Quantitative Protein Measurements 
5µl of all samples (known and unknown) are added to 5µl of loading dye. These samples are 
run on an SDS-PAGE gel and then stained using Commassie Blue stain. The gel is destained 
thoroughly using destaining solution. The gel is rehydrated with deionised water for 15 minutes 
or until the has returned to its original size. The gel is scanned using the Odessey gel Scanner. 
The intensity of the bands is then calculated using the Image Studio Lite Gel Analysis program. 
The intensity levels of the known samples are mapped on an excel graph and the concentrations 
of the unknown samples are calculated based on the equation of this graph. BSA standards are 
used as the known samples.  
Running a Western with Cell Lysate 
Prepare a gel with the correct percentage for the protein you are trying to identify and prepare 
running buffer. Add roughly 30ng of protein to each lane. Amounts will vary with different 
concentration levels. Run gel at 180V for 1hr. Transfer at 100v for 1hr or 30V overnight. 
Optional: Stain with ink for 15 mins – 1 drop of ink in 15ml of PBST while shaking. Wash 
three times with 15ml PBST while shaking for 5/10 mins. Block with 5% PBST milk for 
30mins-1hr while shaking. Add primary antibody for 1hr. (If left overnight dilute in 15ml of 
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5% PBST milk on the shaker in cold room) Wash three time with 15ml PBST while shaking 
for 5/10mins. Add secondary antibody 2.5ml of 5% PBST milk for 1hr. Wash three times with 
15ml PBST while shaking for 5/10 mins. Develop using ECL.  
Developing using ECL 
Create your ECL solution by adding equal parts of ECL1 and ECL2 to a falcon tube. Total 
volume of 2ml is sufficient for 1 blot. (Solution must be mixed directly prior to use) Add 
solution directly to blot and leave for 1 min. Blot off excess solution using absorbent paper. 
Attach blot to glass plate with cling film. Develop for periods of 5 seconds, 10 seconds, 5 
minutes and 10 minutes.  Draw in ladder on developed blot.  
  
PCR Protocols: 
Before starting the PCR process, the primers must be tested to determine their optimum 
temperature. This is usually 3°C higher than then lowest temperature primer. DNA must be 
extracted from the wild type cell using the Quiagen DNA extraction kit.  
Total Volume: 20µl HF Phusion Protocol  
2x Phusion HF: 10µl 
10µM Forward Primer: 0.1µl 
10µM Reverse Primer: 0.1µl 
DNA: 250ng 
DMSO: 0.6µl 
ddH2O: Variable  
 
Running Sequence: 
Step  Temperature Time 
Initial Denaturation  98°C 30 Seconds 
 98°C 10 Seconds  
Annealing  Variable (45°C -72°C) Variable (depends on length between 
primers) 
 72°C 10 Seconds 
Final Extension  72°C 10 Minutes 
Hold  4°C Forever  
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PCR Purification Protocol for Sequencing 
PCR products are purified using the Quiagen Purification Kit. The concentration of the 
purified product is calculated using the nanodrop machine.  
Freezing Cells 
Samples are trypsonised for 5 minutes. The trypsonisation reaction is stopped by adding 10ml 
of media. The cells are then spun down at 1000rpm for 5 minutes. The supernatant is removed 
and the pellet is resuspended in 3ml of freezing media. 1ml of the sample is aliquoted into 
cryotubes and placed in a freezing pack. The freezing pack is placed at -80°C for one week. 
Following this the cryotubes can be removed from the freezing pack and placed in normal 
storage boxes at 80°C. When the cells are needed again, the cryotubes should gentle thawed on 
ice. When fully defrosted the 1ml of defrosted cells is added to 9ml of media in a P100 plate. 
The media on this plate is changed after 24 hours. The cells should not be split for at least 48 
hours as they will be quite sensitive.  
Plasmid Design: 
To design my CRISPR guide RNA I used the MIT optimizer website. This website scans the 
desired genome for guide sites and gives them a score based on their number of off-site targets. 
A high score (>90) is preferred. The website generates a 20bp oligo based on these criteria. 
Bases were then added to either end to ensure smooth ligation into the plasmid. The reverse 
oligo is designed based on the generated forward oligo. These oligoes must be annealed before 
they are ligated.  
Plasmid Digestion: 
Cut the lentiviral CRISPR vector using the BsmB1 restriction enzyme (NEB). The restriction 
enzyme is 10000u/ml. 1 unit digests 1µg. 10µg of DNA is needed for digestion which is the 
equivalent to 1530ng/µl as the concentration of DNA is 600ng. Therefore, 1µl of restriction 
enzyme was used.  
Vector used = 16.6 µl 
Enzyme (BsmB1) = 1µl 
Buffer 3.1 (10X) = 5µl 
De-ionised H2O = 27.33 
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The reaction was carried out in a heating block at 55⁰C for 1hr in a total volume of 50µl. 
Following this the mixture was heated at 80⁰C for a further 20 minutes. Following this 1µg of 
phosphatase enzyme was added and left at 37⁰C for 1hr.  
(A phosphatase reaction is needed in order to remove the phosphate group on either end of the 
cut plasmid in order to prevent them from re-circularizing. This will ensure that the guide RNA 
can anneal properly.) 
 
Gel Purification of Digested Plasmid 
To make a 1% agarose gel measure out 1g of agarose and mix it with 100ml of 1 X TAE buffer. 
Heat in the microwave for approx. 4 mins, stirring occasionally. Allow it to cool at room 
temperature. When it has sufficiently cooled safe green is added at 1:10000. Finally pour it into 
the apparatus and allow to cool and set for at least an hour. Before running the gel, a loading 
buffer must be added to the DNA mixture. Run the gel at the 100v for 30-45 minutes. After the 
gel has run use a clean sharp scalpel to cut your DNA at the 12KB band. This band should be 
the 13KB cut vector. The DNA can now be extracted using the Quiagen Gel Extraction Kit.  
 
Annealing the pairs of Oligos: 
The forward and the reverse strands of the guide RNA must be annealed together to form a 
double stranded DNA insert that can be ligated with the backbone of the cut plasmid. To do 
this there must be equal concentrations of the forward and reverse strands and a 10X T4 ligation 
buffer. This experiment should be carried out at 10µl so to make up the final concentration we 
add ddH20.  
               1 µl forward strand (100 µM) 
               1µl of reverse strand (100µM) 
               1µl of 10X T4 ligation buffer (NEB) 
               7µl of dd H2O  
The tube is place in a water filled hole in the heat block at 95⁰C for 5 mins. Following this the 
heating block is then switched off but the tube remains in it and is allowed to cool down to 





For the ligation reaction there must be a defined molar relationship between the insert and cut 
plasmid. The most common ratios are 1:0.5, 1:1, 1:2 & 1:3. The reaction takes place at 10µl so 
100ng of the backbone plasmid is needed. The plasmid used was 75ng/µl and so 1.25µl was 
used to make up the concentration. The concentration of insert was calculated based on ration 
as well as other factors such as vector size, vector ng and insert size. This calculation was 
carried out using the INSILICO ligation calculator. http://www.insilico.uni-
duesseldorf.de/Lig_Input.html 
 1:0.5  1:1 1:2 1:3 
T4 Ligase (µl) 1 1 1 1 
T4 Buffer 10X (µl) 1 1 1 1 
Backbone Plasmid 
(µl) 
1.25 1.25 1.25 1.25 
Insert (µl) 0.328 0.657 1.309 1.971 
ddH2O (µl) 6.422 6.093 5.441 4.779 
 
The tubes were kept at 16⁰C over night.  
 
Transforming the Competent Cells: 
Add 2µl of each of the ligation reaction to 50µl Stb3 cells. Incubate for 30 minutes on ice. 
Following this heat shock at 42⁰C for 60 seconds. Return the tubes to ice for 3 minutes then 
add 50µl of LB to each tube. Incubate the tubes for 1 hour in the 37⁰C shaker. After this 
inoculate agar plates with two concentrations of each ligation ratio; 10µl and 50µl. Incubate 
these place at 37⁰C overnight.  
 
Plasmid sequencing: 
15µl of each plasmid ratio being sequenced was sent along with 5µl of the primer per tube. 
Plasmid concentration was 100ng. To achieve the correct concentration, the plasmid was 
41	
	
diluted using EB buffer. 2µl of plasmid was added to 17µl of EB buffer and the Nano Drop 
was used to analyse the new concentration. Using this as a base small amounts of EB or plasmid 
were added to achieve the correct concentration. P.F. primer that has a concentration of 3.2µM 
was used. A concentration of 0.1µM was needed and so 1.6µl of the primer was added to 48.4µl 
of H2O. The promoter used was U6.  
Nano drop 
The nanodrop can be used to test genomic DNA concentrations. 1µl of the buffer the DNA is 
diluted in is placed on the nanodrop and blanked. 1µl of the DNA sample is placed on the 
nanodrop and its concentration is recorded. This is repeated 3 times and an average 
concentration of the DNA is calculated.  
Double Digestions: 
Double digestion can be used in order to ensure that the plasmid has been effectively cut by 
the BsmB1 restriction enzyme leaving a 2KB deletion in the plasmid (it cuts in two places). In 
this double digestion the restriction enzymes BamH1 and BspD1. BspD1 has a restriction site 
in the segment that should have been cut and so this should not have any effect of on the 
plasmid if it has been effectively cut. The second digestion enzyme used was BamH1. This 
restriction enzyme has a site in the 13KB plasmid and so it should cut the plasmid into two 
segments, one roughly 5KB and the other 8KB. This can be shown when run on an agarose 
gel.  
 Plasmid 1 Plasmid 2 Plasmid 3 Plasmid 4 Full Lentivirus 
Plasmid 
BamH1 (µl) 0.25 0.25 0.25 0.25 0.25 
BspD1 (µl) 0.5 0.5 0.5 05 0.5 
10X Cut Smart 
(µl) 
4 4 4 4 4 
Plasmid (µl) 10 5 5 5 2 







The plasmids were cotransfected with GFP for FACS cell sorting.  
4mg of Plasmid 
4mg of GFP 
15µl of Attractane 
Variable amount of free media (Media with no FBS or pen strip)  
Total Volume: 300µl  
 
The wild type Siha cells were transfected when they were roughly 60% percent confluent and 
then they were sorted 48 hours later when they were roughly 90-100%.  
Electroporation: 
Three p100 plates of 90% confluent Siha cells were washed and trypsonised as usual. Media 
was then added up to 10ml. All the media was added into a 50ml falcon and was spun down 
at 1000rpm for 5 minutes. The supernatant was removed and the pellet was resuspended in 
2ml of media. 10µl of cells and 10µl trypsin blue were added together and 10µl of this 
solution was placed in a cell counter slide and the number of cells were calculated using the 
cell counter. 1 million cells were needed for the electroporation and so based on the number 
of cells present I calculated that I needed 390µl of the cell media. This 390µl was placed in 
an Eppendorf and was spun at 300g for 7 minutes. The supernatant was removed and the 
pellet was resuspended in 100µl of Cell Line Nucleofactor Solution T, 2µg (6.5µl) of plasmid 
and 1.2µg (3µl) of GFP from the electroporation kit. (The following steps must be undertaken 
quickly as the Nucleofactor is toxic to cells) This solution was added to a cuvette and placed 
in the Nucleofactor Device and the program V-23 for high expression was selected. Once the 
program had finished I added 500ml of media to the cuvette. This was then transferred to 
1.5ml of media that had been previously incubated in a 6-well plate. I added 200µl (0.5 
million cells) to an adjacent well and made up to 2ml with media to act as a control. These 
cells will be left for 90hrs before FACS cell sorting. The media on the cells were changed 






FACS Cell Sorting: 
Before cell sorting the cells are trypsonised as usual. Media is added to stop the reaction and 
the cells are added in a fresh 15ml falcon tube. They are spun at 1000rpm for 5 minutes. The 
supernatant is removed and the pellet is resuspended in 0.2ml of PBS.  
2 x 96 well plates containing 200µl of media and one falcon tube containing 2ml of media are 
prepared per sample.   
 
Single Chain Purification: 
A sterile tip was used to scrape the starter culture (plasmid in a glycerol stock). This tip was 
placed in a falcon tube containing 5ml of fresh LB, 10% Amp and 0.1% glucose. (Glucose is 
used to stop expression of the plasmid before transfection i.e. leaky expression) This was left 
shaking at 37°C overnight. The following day this 5ml was added to 250ml of fresh LB with 
10% amp and 0.1% of glucose. This was left shaking at 37°C until the OD600 levels were 
between 0.4 and 0.6. The OD level was checked after 1hr and then every 20 minutes after that 
until the OD600 level was at 0.555. This took roughly 2.5hrs. 1ml of this solution was spun 
down at 13,200rpm for 15mins at 4°C and frozen in liquid nitrogen. This sample will be run 
on a commassie gel later. 
Plasmid Induction Protocol A: 
I then added 250µl of 1M IPTG to the rest of the solution and left it shaking at 30°C overnight. 
The next morning the flask contents were diluted 1:1 with fresh LB and the OD600 absorbance 
levels were measured at 1.621 and 1.747 respectively. A 1ml aliquot was taken, spun down at 
13,200rpm at 4°C for 15mins and frozen in liquid nitrogen. This sample will be run on a 
commassie gel later. The rest of the sample was spun down at 4000rpm at 4°C for 40mins. The 
pellet was then resuspended in 10ml of PBS.  
Plasmid Induction Protocol B: 
I added 250µl of 1M IPTG to the rest of the solution and left it shaking for 6hrs at 37°C. I 
checked the OD600 level every hour and took a 1ml aliquot and spun it down at 13,200rpm at 
4°C for 15 mins. After the 6 hours I spun the rest of the sample down at 4000rpm at 4°C for 40 




Plasmid Induction Protocol C 
I added 250µl of 1M IPTG to the rest of the solution and left it shaking for 3hrs at 37°C. I 
checked the OD600 level every hour and took a 1ml aliquot and spun it down at 13,200rpm at 
4°C for 15 mins. After the 3 hours I spun the rest of the sample down at 4000rpm at 4°C for 40 
minutes. The supernatant was discarded and the pellet was resuspended in 10ml of PBS. 
Purification of the plasmid  
100µl of 10% Triton x100 is added and the tube is placed on the rotator in the cold room for 
30mins. Following this the tube was sonicated 6 x 15 seconds with a 30 second interval 
inbetween or until the sample has a consistency of water. The solution is then decanted into 
1.5ml Eppendorf’s and spun down at 13,200rpm for 15 minutes at 4°C. The supernatants (cell 
lysate) were collected together and filtered twice, once through a 45µM filter and once through 
a 22µM filter. A 20µl aliquot was taken and frozen in liquid nitrogen. This sample will be run 
on a commassie gel later. 50µg of protein A Sepharose Resu powder was added to 600µl off 
ddH2O and was dissolved by gently inverting the tube. Using the lowest centrifuge setting the 
Eppendorf is spun for 30 secs three times, discarding the supernatant inbetween. 550µl ddH2O 
was added to the beads and this was then added to the cell lysate. This mixture as then placed 
on the rotating wheel in the cold room for 1hr. Following this the mixture was added to a 10ml 
column and the flow-through was collected and frozen in liquid nitrogen. After the flow-
through was collected the beads were washed 5 times with 1ml of a PBS+1% triton solution. 
These washes were collected and frozen in liquid nitrogen. The single chain was then eluted 
with 500µl of 0.2M glycine pH2. The elutes were collected in a tube which contained 75µl of 
1M Tris pH 9. Five elutes were collected in total and they were kept at 4°C.  
All of the sample aliquots taken, the flow-through, the washes and the elutes were run on 12% 
SDS PAGE gels. The gels were then stained using commassie blue stain for 35 minutes and 
then destained using destaining solution overnight.   
 
Elisa Protocol: 
Coat 20 wells of an ELISA plate with 100ng of protein in 50µl carbonate mix. Coat 10 control 
wells with 50µl of just carbonate mix. Leave overnight at 4°C. Wash 5x with PBST. Blocked 
for 1hr in 100µl of 3% BSA-PBST. Variety of dilutions were used as the primary antibody. 
Primary antibody was left shaking for 1hr. Wash 5 x 200µl PBST. Secondary was added at a 
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dilution 50µl per well and left shaking. Wash 5 x 200µl PBST. 50µl of ECL I and ECL II 
mixture was added to each well and developed using fluorescent machine. 
 
Dot Blot Protocol: 
2µl of protein is added to a membrane. Membrane is blocked in 15ml of 5% PBST-Milk for 
1hr. Primary is added for 1hr. Wash x3 PBST. Secondary is added for 1hr. Wash x3 PBST. 



























3.1 Interferon Induction of the ISG15 Pathway  




Figure 3.1.1: Western Blot Analysis of ISG15 Expression After INF Treatment 
Image A shows the INFα induced ISG15 blot and Image B shows the INFβ induced 1SG15 blot 
 
   
In Figure 3.1.1, Image A three P100 plates of 80% confluent wild type siha cells were transfected 
with 1µg of INFα and left for 24, 48 and 72 hours respectively. In Figure 3.1.1, Image B three 
P100 plates of 80% confluent wild type siha cells were transfected with 1µg of INFβ and left 
for 24, 48 and 72 hours respectively. A P100 plate of 95% confluency that had not been treated 
was also harvested and used as the wild-type control. These cells were lysed with 8M Urea 
buffer and 30µg of protein was loaded on a 15% SDS-PAGE gel. Primary antibody used was 
polyclonal rabbit anti-ISG15 at 1 in 2500. Secondary used was mouse anti-rabbit antibody at 1 
in 1000. Blot was developed for 12 mins. 
47	
	
In Image A the bands are much more faint than those in Image B despite the fact that 30µg of 
protein was loaded on each gel. This suggests that ISG15 in more highly expressed in cells 
treated with INFβ than those treated with INFα.  




In Figure 3.1.2, 9 P100 plates of 80% confluent wild type siha cells was transfected with 1µg of 
INFβ each and were left for 1, 2, 5, 7, 16, 18, 24, 48 and 72 hours respectively. A P100 plate of 
95% confluency that had not been treated was also harvested and used as the wild-type control.  
These cells were lysed with 8M Urea buffer and 30µg of protein was loaded on a 15% SDS-
PAGE gel. Primary antibody used was polyclonal rabbit anti-ISG15 at 1 in 2500. Secondary 
used was mouse anti-rabbit antibody at 1 in 1000. Blot was developed for 2 minutes. 
From this Figure 3.1.2 it is clear that the cells need to be transfected for at least 5 + hours for 
the ISG15 levels to be seen. The level of ISG15 increases steadily until 18 hours’ post-
transfection where it begins to level off. The bands become clear after 16 hours with 18 hours 
seeming the peak time as it shows the clearest band. No bands can be seen in the first 2 hours 










3.1.3 INFβ induction of ISG15 Conjugation: 
 
 
Figure 3.1.3: Western Blot Analysis of ISG15 Conjugates 




In Figure 3.1.3, 9 P100 plates of 80% confluent wild type siha cells was transfected with 1µg of 
INFβ each and were left for 1, 2, 5, 7, 16, 18, 24, 48 and 72 hours respectively. A P100 plate of 
95% confluency that had not been treated was also harvested and used as the wild-type control. 
These cells were lysed with 8M Urea buffer and 30µg of protein was loaded on a 15% SDS-
PAGE gel. Primary antibody used was polyclonal rabbit anti-ISG15 at 1 in 2500. Secondary 
used was mouse anti-rabbit antibody at 1 in 1000. Blot 1 was developed for 20 minutes and 
blot 2 was developed for 2 minutes.  
In Image A we can see multiple bands in each lane of the gel and these lanes are very dark and 
prominent. These bands are ISG15 conjugated to different proteins. In Image B we can also 
see multiple bands in each lane of the gel. These bands are much fainter however than those in 
image 1. No significant difference is seen between the different lanes in either gel. The bands 















Figure 3.1.4: Western Blot Analysis of Interferon Induction of IRF1 and IFITM1 
Image A shows IFITM1 following interferon induction. Image B shows IRF1 following interferon induction. 
 
 
In Figure 3.1.4, a P100 plate of 80% confluency was transfected with 1µg of INFα and was 
harvested after 24 hours. A separate P100 plate of 80% confluency was transfected with 1µg of 
INFβ and was harvested after 24 hours. A P100 plate of 95% confluency that had not been treated 
was also harvested and used as the wild-type control. These cells were lysed with 8M Urea 
buffer and 30µg of protein was loaded on a 15% SDS-PAGE gel. In Image A, the primary 
antibody used was mouse anti-IRF1 at 1 in 1000. The secondary used was a rabbit anti-mouse 
antibody at 1 in 1000. In Image B, the primary antibody used was the Til anti-IFITM1 antibody 
at 1 in 1000. The secondary used was a rabbit anti-mouse antibody at 1 in 1000. 
In both images of figure 3.1.4 bands can only be seen in the lanes that had been treated with 










3.2 CRISPR CAS Process  
3.2.1 CRISPR Cas RNA targeting Exon 2:  
The CRISPR RNA designed was transfected into Siha cells using GFP and attractene and sorted using 
FACS cell sorting. These cells were grown in 96-well plates. Clones were grown in separate wells of 
6-well plates and were tested to see if they were positive CRISPR clones using PCR techniques and 
sequencing.  
 
Figure 3.2.1:		Agarose gel analysis of Exon 2 CRISPR PCR 
The DNA is from cells which have been transfected with Exon 2 
CRISPR RNA. The short PCR primers were used for these samples.	
 
In Figure 3.2.1 the HF Phusion protocol was used and the resulting PCR product was run on a 
1% Agarose TAE gel. The numbers on the lanes represent the names of the clones grown. We 
can see that there are multiple lanes that contain no bands. This could be due to low levels of 
DNA present or to the fact that the genome has been altered and that the primer region of the 







In Figure 3.2.2 the HF Phusion protocol was used and the resulting PCR product was run on a 
1% Agarose TAE gel. Again, we can see that there are multiple lanes that contain no bands. 
This could be due to low levels of DNA present or to the fact that the genome has been altered 
and that the primer region of the genome has been altered.  
 
In Figure 3.2.3 the HF Phusion protocol was used and the resulting PCR product was run on a 
1% Agarose TAE gel. The samples which showed no bands in the previous experiment were 
run again to make sure there were no mistakes. Sample 19 and the wild type control showed 
bands, meaning that the PCR worked this time and that the lack of bands in the previous 
experiment was likely an experimental error.  
Following this experiment, the pure DNA of the seemingly negative samples were run on a 1% 
agarose TAE gel. The gel analysis showed that the DNA concentration of samples 8 and 19 
were too low to be seen on a gel. This suggests the reason no bands were seen following the 
PCR reaction was due to the fact that there was negligible DNA present.   	
Figure 3.2.2: Agarose gel analysis of Exon 2 CRISPR PCR 
The DNA is from cells which have been transfected with Exon 2 CRISPR RNA. The DNA is from cells which 
have been transfected with Exon 2 CRISPR RNA. The short PCR primers were used for these samples.	
Figure 3.2.3:	Agarose gel analysis of Exon 2 
CRISPR PCR 
The DNA is from cells which have been transfected 
with Exon 2 CRISPR RNA. The short PCR primers 




To ensure that the genome of the potentially positive CRISPR clones was intact and not 
completely disrupted, a PCR reaction was carried out using the HF Phusion protocol and the 
p53 primer. The resultant product was then run on a 1% Agarose TAE gel. From Figure 3.2.4 
we can see this PCR protocol worked and that area of the p53 primers are still intact.  
	
In order to narrow down the area of the deletion, new primers were designed further apart from 
the original primers. This PCR reaction was carried out using the HF Phusion protocol and the 
resultant product was run on a 1% Agarose TAE gel. From this gel we can see that there are 
bands in every lane. This indicates that the area of the long primers is intact and the deletion is 
likely between these two long primers.  
	
Figure 3.2.4: Agarose gel 
analysis of Exon 2 CRISPR PCR  
P53 primers were used for these 
samples.		
Figure 3.2.5: Agarose gel analysis of 
Exon 2 CRISPR PCR 





In an effort to further narrow down the area of the deletion, new primers were designed that 
were located between the long primers and the original short primers.	This PCR reaction was 
carried out using the HF Phusion protocol and the resultant product was run on a 1% Agarose 
TAE gel. From Figure 3.2.6 we can see that there are bands in every lane. This indicates that 
the area of the medium primers is intact and the deletion is likely between these two medium 
primers.  
	
To further narrow down this area, the medium and short primers were mixed to test different 
areas for the presence of the deletion. This PCR reaction was carried out using the HF Phusion 
protocol and the resultant product was run on a 1% Agarose TAE gel. Again, in Figure 3.2.7 
we can see that there are bands present in every lane. These primers identify very specific 
regions of the genome that are very close to the area identified by the short primers. The fact 
that there are bands present indicates that the results from the short primers may not be as 
accurate a previously believed. Only sequencing results can confirm this. 
Figure 3.2.6: Agarose Gel Analysis of Exon 2 
CRISPR PCR 
The medium PCR Primers were used on these samples.		
Figure 3.2.7: Agarose Gel Analysis of 
Exon 2 CRISPR PCR 
In this PCR protocol the PCR primers were 
mixed in an attempt to try and narrow down 














Figure 3.2.8: Sequencing Results for Sample 6, Sample 12 and Sample 31 
Sequencing performed by the Cambridge branch of Science Biosource 
55	
	
To prepare the DNA for sequencing a PCR HF Phusion protocol was carried out at 50µl 
using the medium primers. 5µl of the resulting reaction was run on a gel to ensure that the 
PCR reaction had worked. Following this the remaining PCR reaction was prepared for 
sequencing using the Quiagen PCR Purification Kit. The DNA and primers were sent to 
Source Bioscience as per their instructions. 	
The sequencing results show that the PCR product is almost identical to the original genome 
sequence. Sample 6 and Sample 12 were 98% identical and Sample 31 was 99% identical to 
the original genome. This suggests that the genome has not been altered. The small differences 
between the CRISPR samples and the original genome is likely due to a sequencing error. 
There were multiple Ns in the CRISPR sequencing suggesting that not all the bases were 











3.2.2 CRISPR Cas RNA targeting the C-Terminus:  
As the results showed there the targeting of Exon 2 did not seem to work, the experiment was 
repeated. A new CRISPR RNA was also designed to target the C-Terminus. The CRISPR RNA 
for the C -Terminus and Exon 2 was designed was transfected into Siha cells using the 
electroporation technique and sorted using FACS cell sorting.  These cells were grown in 96-
well plates. Clones were grown in separate wells of 6-well plates and were tested to see if they 




To determine whether the CRISPR RNA had altered the genome a PCR was run and then the 
results were analysed using agarose gels. In this figure the HF Phusion protocol was used and 
the resulting PCR product was run on a 1% Agarose TAE gel. The numbers on the lanes 
represent the names of clones grown. Bands can be seen in all lanes in this gel. 
 
Figure 3.2.9: Agarose Gel 
Analysis of CRISPR Sample 2 
and Sample 3 PCR 
 
Sample 2 DNA are from the cells 
transfected with the C-Terminus 
CRISPR RNA. Sample 3 DNA are 
from the cells transfected with the 
Exon 2 CRISPR RNA.  
The long primers were used for the 
Sample 2 PCR and the short primers 





In Figure 3.2.10, a P100 plate of 80% confluency, of each CRISPR clone, was transfected with 
1µg of INFβ and was harvested 24 hours later. A P100 plate of 95% confluency of each clone 
was also has harvested, untreated. A 95% confluent P100 plate of wild-type Siha cells were also 
harvested to use as a control. These cells were lysed with 8M urea buffer and 30µg of protein 
was loaded on a 15% SDS-PAGE gel. Primary antibody used was polyclonal rabbit anti-ISG15 
at 1 in 2500. Secondary used was mouse anti-rabbit at 1 in 1000. This blot was developed for 
5 minutes.  
In this Figure 3.2.10 we can see that bands are only present in the lanes which have been treated 
with interferons. No bands are seen in the wild-type lane or in the lanes with CRISPR cells that 
have not been treated with INFβ. As ISG15 protein can be seen after INF transfection, it 
suggests that the ISG15 gene has not been knocked down. Faint bands can be seen in Lane 3 
(2.1 INF) and Lane 6 (2.2 INF) between the 10kDa and 17kDa markers, underneath the ISG15 




Figure 3.2.10: Western Blot Analysis of Wild-type, CRISPR and INF-treated CRISPR Cells 
 
Lane 1: WT, Lane 2: 2.1, Lane 3: 2.1 INF, Lane 4: WT, Lane 5: 2.2, Lane 6: 2.2 INF, Lane 7: WT, Lane 8: 





Figure 3.2.11: Western Blot Analysis of Wild-type, CRISPR and INF-treated CRISPR Cells 
Lane 1: 2.5, Lane 2: 3.1, Lane 3: 3.2, Lane 4: 3.3, Lane 5: INF 2.5, Lane 6: INF 3.1, Lane 7: INF 3.2, Lane 8: 
INF 3.3 
 
A P100 plate of 80% confluency, of each cell line, was transfected with 1µg of INFβ and was 
harvested 24 hours later. A P100 plate of 95% confluency of each cell line was also has 
harvested, untreated. A 95% confluent P100 plate of wild-type Siha cells were also harvested to 
use as a control. These cells were lysed with 8M urea buffer and 30µg of protein was loaded 
on a 15% SDS-PAGE gel. Primary antibody used was polyclonal rabbit anti-ISG15 at 1 in 
2500. Secondary used was mouse anti-rabbit at 1 in 1000. This blot was developed for 5 
minutes.  
In this Figure 3.2.11, we can see that bands are only present in the lanes which have been 
treated with interferons. No bands are seen in the wild-type lanes or in the lanes with CRISPR 
cells that have not been treated with INFβ. As ISG15 protein can be seen after INF transfection, 
it suggests that the ISG15 gene has not been knocked down. In this image we can see that there 
are clear bands around the 10kDa marker, below the ISG15 protein. Again, these bands suggest 
that there may be a heterozygous deletion/mutation present.  Based on these results, the 





Figure 3.2.12: Western Blot Analysis of Wild-type, CRISPR and INF-treated CRISPR Cells 
Lane 1: WT, Lane 2: 2.5, Lane 3: 2.5 INF, Lane 4: WT, Lane 5: 3.1, Lane 6: 3.1 INF, Lane 7: WT, Lane 8: 3.2, 
Lane 9: 3.2 INF, Lane 10: WT, Lane 11: 3.3, Lane 12: 3.3 INF. 
 
This is a repeat experiment using the same cell lysate as figure 3.2.11. The cell lysate had been 
snap frozen using liquid nitrogen and was stored overnight at -80°C. The lysate was thawed on 
ice and was used at the same concentration that had been determined via Bradford reagent the 
previous day. 30µg of protein was loaded on a 15% SDS-PAGE gel. Primary antibody used 
was polyclonal rabbit anti-ISG15 at 1 in 2500. Secondary used was mouse anti-rabbit at 1 in 
1000. This blot was developed for 5 minutes.  
Again in Figure 3.2.12 we can see that bands can only be seen in the lanes treated with INF. 
There are also faint bands on this gel below the ISG15 protein, around the 10kDa marker. In 
the previous figure these bands can be seen in all lanes treated with INF yet in this gel the bands 
can only be seen in Lane 9 (3.2 INF) and Lane 12 (3.3 INF). It is not clear why the bands can 
no longer be seen in 2.5 INF and 3.1 INF. The protein may have started to deteriorate after 
being frozen and thawed or it may be that the first image had been an experimental mistake. 
Sequencing results will be necessary to determine if the genome of these cells has been altered.  
Sequencing was attempted with these samples yet due to DNA contamination, clear results 





3.3 Single Chain Purification of ISG15: 
3.3.1 Plasmid Induction Single Chain Protocol A 
	
A 1ml aliquot was taken of the bacterial culture before induction with 1M IPTG and a 1ml 
aliquot was taken after induction when the OD level was 0.445. These samples were spun down 
at 13,200rpm for 15 mins at 4°C. The pellets were resuspended in varying amounts of PBS 
depending on their OD600 measurements. These samples were sonicated at 10.0 amp in the 
cold room. The sample taken before induction was sonicated 6x5 seconds with 30 second 
intervals on ice. The sample taken after induction was sonicated 10x5 seconds with 30 second 
intervals on ice. After sonication 50µl of both samples were taken and labelled Whole Cell 
Before Induction and Whole Cell After Induction respectively. The remainder of the samples 
were spun down at 6000rpm for 20 minutes at 4°C. The supernatant was removed and placed 
in tubes labelled Cell Lysate Before Induction and Cell Lysate After Induction respectively. 
10µl of each sample was added to 10µl of Loading Dye 0.25M DTT. These sample were boiled 
at 95°C for 3 mins and loaded onto a 15% SDS-PAGE gel. The gel was run for 45mins at 170V 
and was stained in 15ml of Commassie Brilliant Blue Solution and then destained using 
destaining solution.  
The plasmid, if expressed, should be roughly 26kDa in size. No distinct bands can be seen at 
this size. This may indicate that the plasmid is not present or it may indicate that it is present 




Figure 3.3.1: Commassie Gel Analysis of 
Bacterial Culture Samples 
 
Lane 1: Whole Cell Before Induction Lane 2: Whole 
Cell After Induction Lane 3: Cell Lysate Before 




These elutes were obtained using protocol A. As we can see there are no bands in the elute 
lanes. If the single chain was present in the elutes we would see a band around the 26kDa. In 
lanes 6, 7 and 8 of Figure 3.3.2 we see bands around the 65kDa mark, these are the BSA 
standards. The BSA standards are used to give an indication of the quantity of the single chain 
if the single chain is present.  
10µl were added into each lane (5µl of protein and 5µl of 0.25M DTT Loading Dye). The gel 





In Figure 3.3.3 10µl was added to each lane (5µl of protein and 5µl of 0.25M DTT Loading 
Dye). The gel was stained using 15ml of Commassie Brilliant Blue Solution and then destained 
using destaining solution. The washes and flow-through were obtained from Protocol A. These 
Figure 3.3.2: Commassie Gel 
Analysis of Single Chain Elutes and 
Bradford Standards  
Lane 1: Elute 1, Lane 2: Elute 2, Lane 
3: Elute 3, Lane 4: Elute 4, Lane 5: 
Elute 5, Lane 6: 0.1µg BSA standard, 
Lane 7: 0.2µg BSA standard, Lane 8: 
0.5µg BSA standard  
 
Figure 3.3.3: Commassie Gel Analysis 
of Protocol A Single Chain Washes 
and Flow-Through 
Lane 1: Flow-through Lane 2: Wash 1 
Lane 3: Wash 2 Lane 4: Wash 3 Lane 5: 




samples are run on a gel to ensure the single chain hasn’t been washed through in the washes 
which can sometimes occur.  
 
3.3.2 Plasmid Induction and Purification of Single Chain Protocol B and C 
 
10µl was added in each lane. (5µl of protein and 5µl of 0.2M DTT Loading Dye). The samples 
were incubated at 37°C for 10 minutes prior to being run on the gel. The gel was then stained 
with Brilliant Blue Commassie Stain and destained using destaining solution. From Figure 
3.3.4 we can see that there is very little protein in the washes and flow-through from Protocol 
B. This combined with the fact that no protein was found in the elution’s suggests that the 
plasmid was not efficiently induced and the single chain is likely not present. In the flow-
throughs and first wash of protocol C we can see an abundance of protein. Some of the single-
chain seems to have been eluted into the flow-through and first wash as a band can be seen 
around the 36kDa mark. This would be roughly the size of the single chain in its dimer form. 
The single chain was also found in the elutes however so it was not entirely lost in the washes.  
 
Figure 3.3.4: Commassie Gel Analysis of 
Protocol B and Protocol C Single-Chain 
Washes and Flow-Throughs 
Lanes 1-6 were from Protocol B and Lanes 7-12 
were from Protocol C 
Lane 1: Flow-through Lane 2: Wash 1 Lane 3: 
Wash 2 Lane 4: Wash 3 Lane5: Wash 4 Lane 
6: Wash 5 Lane 7: Wash 1 Lane 8: Wash 2 
Lane 9: Wash 3 Lane 10: Wash 4 Lane 11: 




The elutes from protocol B show only very faint bands around the 36kDa marker. The faintness 
of these bands compared to the BSA standards shows that their concentrations are likely too 
low to be functional. Elutes 1, 2 and 3 of protocol C show more distinct bands around the 
36kDa marker. These bands are likely the single chain protein. Based on the faintness of the 
elute bands to the BSA standard bands shows that the concentration of the elutes are likely to 
be low yet it is worth testing their affinity.  
3.3.3 Testing the Affinity of the Purified Single Chain 
 
 
Figure 3.3.6: Quantification Analysis Purified Single Chain 
Lane 1: Protocol B Elute 3, Lane 2: Protocol C Elute 1, Lane 3: Protocol C Elute 2 Lane 4: 0.01µg BSA, Lane 
5: 0.03µg BSA, Lane 6: 0.05µg BSA, Lane 7: 0.1µg BSA 
 
 
Figure 3.3.5: Comassie Gel Analysis of 
Protocol B and Protocol C Elutes and 
BSA Standards 
Lanes 1-5: Protocol B Elutes 1-5, Lanes 6-
10: Protocol C Elutes 1-5, Lanes 11-13: 
BSA standards 0.1µg, 0.2µg and 0.5µg. 
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The concentration of the single chain is far too low to test using common protein quantification 
techniques such as using a Bradford reagent. To test the concentration of the single chain, 
quantitative analysis on a commassie gel was performed. The gel was stained with 15ml of 
Brilliant Blue Commassie Stain and destained thoroughly using destaining solution. The gel 
was then scanned using Odessey Gel scanner and was analysed using Image Studio Lite 
Western Gel Analyser. The intensity levels of the BSA standards were plotted on graph against 
their concentrations. The concentrations of the elutes were then calculated using the equation 
of the linear trend line of the graph. From the graph in Figure 3.3.7 we can see that the 
concentration of protocol B elute 3 is too low to analyse. 
 
 
Filling the intensity level of Protocol C elute 3, 3090, into the equation y = 74849x + 2239.7 a 
concentration of 0.012 was calculated.  
When the intensity level of Protocol C elute 2, 1620, was filled into the equation, a negative 
number was obtained. The concentration of Elute 2 was too low to be determined in this 
manner. Using purely visual analysis of Figure 3.3.6, the concentration of elute 1 was 







Figure 3.3.7: Excel Graph 




To test the affinity of the single chain antibody, an ELISA was performed. 50ng of pure protein 
was added to the first 10 wells. Sodium carbonate solution was added to the next 10 wells as a 
control. Titrations of the single chains were used as the primary antibody. The concentrations 
calculated were based on the original single chain concentrations which were later thought to 




The plate was developed using ECL and the ELISA Microplate Reader. The results were 




Figure 3.3.8 Illustration of ELISA Plate Layout 




Based on the graph in Figure 3.3.9 we can see that even in low quantities the single chain has 




Figure 3.3.10: Dot Blot Analysis of ISG15 using ScFv as Primary Antibody 
Image A was the first blot taken. Blot was developed for 5 minutes. Image B was the second blot 
taken. Blot was developed for 12 minutes. 
 
2µl of protein was added in each square. A titration of concentrations of pure ISG15 protein 
was used (1ng – 500ng). 80µl of Elute 2 in 2.5ml of 5% PBST-milk was used as the primary 
antibody. This was the equivalent of approximately 2mg/ml. Primary antibody was left on 
overnight at 4°C. The secondary used was Protein A HRP at 1 in 5000. Blot was developed for 
4 minutes. 
In Image A of Figure 3.3.10, dots can be seen in the squares with concentrations of 1ng, 10ng 
and 100ng. These dot are unclear however due to the dirtiness of the blot. When the blot was 
washed again, a dot could only be seen in the 10ng square. The vigorous washings could have 






10µl was added to each well (5µl of protein and 5µl of 0.2M DTT Loading Dye). A titration 
of concentrations of pure ISG15 protein was used. 80µl of Elute 2 in 2.5ml of 5% PBST-milk 
was used as the primary antibody. This was the equivalent of approximately 2mg/ml. Primary 
antibody was left on overnight at 4°C. The secondary used was Protein A HRP at 1 in 5000. 
Blot was developed for 6 minutes. 
Clear bands can be seen in the first 3 lanes, 1ng, 10ng and 100ng, of the gel in Figure 3.3.11. 


















4.1 Interferon Induction of the ISG15 Pathway 
In Figure 3.1.1 it is clear that there is a stronger induction of protein GAPDH was used as a 
loading control. The induction of ISG15 by type 1 interferons has been well documented 
throughout the literature (Bektas et al. 2008; Dieterich & Relman 2011; Forster 2012) yet few 
papers differentiate between the inducing potential of interferon α and interferon β. This 
experiment ISG15 when cells are transfected with INFβ than when cells are transfected with 
INFα.The bands in figure 3.1.1 Image B are significantly darker to those bands in figure 3.1.1 
Image A. In both blots 30ng of protein was added to each lane and the blots were developed 
for the same length of time. The housekeeping suggests that INFβ has a stronger induction 
potential than IFNα.  
Although INFα and INFβ are both type 1 interferon and have similar structures and functions, 
they are not completely identical. For example, their transcription methods are entirely 
different. The transcription of interferon β is accomplished through the collaboration of 
multiple transcription factors recruited to several specific DNA-binding sites in the VRE of the 
INFβ promoter. (Juang et al. 1998)	Less is known about the transcription of the INFα gene. 
IRF-E and AF-1 are involved however as over-lapping cis-acting elements. The IRF-E site is 
crucial for transcriptional activity. The subtle differences between the two interferons could 
alter their induction potential.  
The differences between the two gels in Figure 3.1.1 could also be due to experimental error. 
The loading controls show the same amount of protein was added to each gel. It also showed 
that there was no transferring error. The experiment should have been repeated to consolidate 
the result yet due to lack of INFα this was not possible. Based on this result, INFβ was used in 
the following the experiments to induce ISG15.  
In Figure 3.1.2 the length of time needed for ISG15 induction was investigated. Zhao et al has 
described transfecting cells for 24 hours in order for ISG15 to be seen clearly on a Western 
blot using commercial antibodies. (Zhao et al. 2005) In order to optimise experimental 
procedure, it is necessary to determine the peak time of ISG15 induction after interferon 
transfection. To do this, Siha cells were transfected with INFβ for varying length of time. When 
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the resulting cell lysate was run on an SDS-PAGE gel, the time at which ISG15 starts to be 
induced can be clearly seen. In the Figure 3.1.2 we can see that ISG15 begins to be induced 
between 2 and 5 hours’ post-transfection as no bands can be seen at the 2-hour mark yet a faint 
band can be seen at the 5-hour mark. This suggests that cells need to be transfected for at least 
5 hours with INFβ in order for ISG15 to be seen on a blot. The level of ISG15 then increases 
steadily until the 24-hour mark where it begins to level off. There is no significant difference 
between the bands at 18, 24, 48 and 72 hours. Peak transfection time seems to be from 18 hours 
onwards with little to no difference between the ISG15 induction levels at the latter time points.  
As previously stated, IG15 has the ability to bind to multiple proteins intracellularly. This 
process is known as ISGylation and the proteins involved play critical roles in multiple vital 
cellular processes. In order to determine the roles of ISG15 conjugates, they must first be 
identified. In this experiment, cells were transfected for 24, 48 and 72 hours respectively. In 
Image B, Figure 3.1.3 only very faint bands can be seen above the ISG15 band. This blot had 
been developed for 2 minutes. No difference can be seen between the lanes that had been 
transfected with interferons. In Image A, Figure 3.1.3 we can see multiple dark bands above 
the ISG15 band. These bands are the ISG15 conjugates. Again in this image we can see that 
there is no significant difference between the lanes that had been treated with interferons. These 
dark bands can even be seen in the wild-type lane. These results suggest the length of 
transfection is not as important in conjugation identification as the length of time developing 
with ECL.  
IRF1 and IFITM1 are integral components of the ISG15 pathway and they are both induced by 
Type 1 interferons. In Figure 3.1.4, in both images, bands can only be seen in lanes treated with 
type 1 interferons. This shows that cells must be interferon stimulated in order for IRF1 or 
IFITM1 to be detected. Therefore, both IRF1 and IFITM1 must not be present in untreated 
cells or, present in such small amounts that they cannot be detected using commercial 
antibodies.  
Based on these results, it is clear that Type-1 interferons are crucial inducers of the ISG15 
pathway. Both interferon α and interferon β are capable of significantly inducing members of 
this pathway, including ISG15, IRF1 and IFITM1, as long as they are transfected for a 





4.2 CRISPR CAS Process 
4.2.1 CRISPR Cas RNA targeting Exon 2: 
The aim of targeting the genome with the CRISPR RNA was to induce a knock-down of our 
target gene, ISG15. There are multiple ways to test if the gene has been knocked down or if the 
genome has been altered in any way. The first test carried out as part of this experiment was to 
design PCR primers that flank the CRISPR RNA. Over 30 CRISPR clones were grown and 
tested. In Figure 3.2.1, the first set of clones were tested. From this figure we see that most of 
the lanes have clear bands around the 300bp mark. This is the correct size for the distance of 
the two primers. Three lanes have no bands. This could be due to an alteration in the genome 
such as a deletion. Alternatively, it could be an experimental mistake such as not enough DNA 
in the PCR mix. The HF Phusion PCR protocol has worked however as the wild-type lane 
shows a band. This proves the annealing temperature and time is correct. In Figure 3.2.2 the 
second set of clones were tested. Again this figure shows that all but three lanes have bands 
around the 300bp. A band is present in the wild-type lane showing the PCR protocol was run 
correctly. The lanes without bands are the potential positive CRISPR clones.  
In Figure 3.2.3 the potential positive clones were run again to alleviate concern of potential 
experimental mistakes. Again in the gel in Figure 3.2.3, a band is seen in the wild-type lane 
showing the PCR protocol has worked. A band is also seen in the clone 19 lane indicating the 
PCR has worked this time. To ensure that the DNA of the potentially positive clones was not 
compromised, the pure DNA was run on an agarose gel. A picture of the gel is not available 
but the results showed that the DNA in clone 8 and clone 17 was too low to be seen on a gel. 
Strong bands were seen in the wild-type, clone 6, clone 12 and clone 31 lanes. Therefore, clone 
6, clone 12 and clone 31 are highly likely to be positive CRISPR clones.  
To test if the genome of the potential positive CRISPR clones are still intact, the HF Phusion 
protocol was run using p53 primers. In Figure 3.2.4 lanes can be seen around the 500bp mark 
in all lanes. This is approximately the size of the distance between the two primers. The bands 
present indicate the genome is still intact.  
To try and identify the area of the supposed deletion, new primers were designed that were 
much further apart than the original primers. In Figure 3.2.5, the products from the PCR using 
the long primers were run on an agarose gel. Bands are seen in all lanes, including the wild-
type lane indicating that the PCR has worked. This result indicates that the supposed deletion 
is between these two primers.  
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To further narrow down the area of the deletion, new primers were designed that are located 
between the long primers and the original primers. In the gel in Figure 3.2.6 bands can be seen 
in all lanes. The PCR protocol has worked as there is a band present in the wild-type lane. The 
deletion is, again, likely to be between these two primers.  
A smaller area is always preferential for sequencing as it increases efficiency. To identify the 
exact location of the deletion, the medium and short primers were mixed. In Figure 3.2.7 bands 
are present in all lanes in the gel. As the area between the two mixed primers is very similar to 
the area between the two original primers, it is very surprising that no deletion is seen. These 
result suggest that perhaps the first set of PCR results were an anomaly despite being repeated.  
In order to determine for sure if a deletion was present in these clones, they were sent for 
sequencing. The sequencing results are shown in Figure 3.2.8. The sequencing results were 
aligned to the original genome sequence using NCBI nucleotide BLAST function. The results 
conclusively prove that there is no deletion in the genome of the clones. Sample 6 and Sample 
12 were 98% identical and Sample 31 was 99% identical to the original genome. The small 
differences between the CRISPR samples and the original genome is likely due to a sequencing 
error. There were multiple Ns in the CRISPR sequencing suggesting that not all the bases were 
correctly sequenced. It is highly probable that the differences are due to the sequencing 
shortcomings. 
Despite the initial positive PCR results the CRISPR Cas process did not work in this case. This 
could be due to a multitude of factors. The CRISPR Cas process is still a very new technique 
that has not been completely optimised. New techniques and programmes such as the MIT 
CRIPSR RNA design program are starting to revolutionise the creation of CRISPR RNA by 
enabling the creation of highly specific oligos that have very low off-targets. The transfection 
and sorting process is also flawed. The cells are transfected with GFP and sorted based on the 
presumptive idea that cells which contain the GFP also contain the plasmid. This is not always 
the case of course. In fact, only approximately one third of cells sorted will contain the plasmid.  
Altering the genome of the cell can also have unknown effects. Many genes play critical roles 
in key cellular functions. Knocking out these genes can be fatal in these cells which will lead 
to the lack of positive clones found. ISG15 plays a crucial role in anti-viral immunity (Pitha-
Rowe & Pitha 2007) as well as multiple other roles when conjugated to a variety of proteins. 
As no other papers have described the effects of a knockdown of ISG15 it is still unknown as 
to whether an ISG15 knockdown is fatal.  
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4.2.2 CRISPR Cas RNA targeting the C-Terminus and Exon 2: 
As the attempt to knockdown ISG15 by targeting the beginning of the coding exon of the gene, 
exon 2, failed, new CRISPR RNAs were designed to target the C-terminus of the gene.  
In Figure 3.2.9 the HF Phusion PCR protocol was run using DNA from the CRISPR clones. 
From here we can see that bands are present in all lanes suggesting that the DNA obtained from 
the CRISPR cells has not be altered. However, a very small deletion may not be seen in a gel 
like this. Running a PCR is just the first step in trying to identify a genome alteration. PCR 
analysis works well to identify large alterations. It is very difficult to identify smaller deletions 
in this manner as the bands can still appear to be similar sized.  
Following these results, the clones were tested using Western Blot analysis. As we have 
previously identified the optimum conditions for identifying ISG15, we applied these 
principals to testing the clones. From the gel in Figure 3.2.10 we can see bands present in the 
lanes that have been treated with INFβ. No bands can be seen in the lanes which have not been 
treated with the type-1 interferon. The fact that bands can be seen in the clones transfected with 
INFβ suggests that the gene has not been knocked down. In Figure 3.2.10 very faint bands can 
be seen around the 10kDa marker in the interferon-treated lanes of 2.1 and 2.2. This band is 
too small to be the ISG15 protein. Identifying a protein this size suggests that there may be a 
heterozygous mutation/deletion present and that this band could perhaps be a truncated form 
of the ISG15 protein. The second set of CRISPR clones were run using the same method. This 
gel can be seen in Figure 3.2.11. In this gel we can see that band can only be seen in lanes 
where the clones had been transfected with type-1 interferons. Again this suggests that the 
ISG15 gene is intact. Also in this gel we see the distinct bands of a smaller protein is present 
around the 10kDa mark in the 3.2 and 3.3 clones which had been treated with INFβ. These 
bands may also be present in the 2.5 and 3.1 INFβ clones but due to the dirtiness of the blot it 
cannot be seen.  
As this blot was not very clear, the same lysate was run again using the same protocol. The 
results, which can be seen in Figure 3.2.12, show a slightly different picture. In this gel the 
smaller band can only be seen in lane 9 which is clone 3.2 treated with INFβ. There are a 
number of reasons why the smaller band may no longer be present in the other interferon treated 
lanes. Firstly, an experimental error could have occurred in the gel in Figure 3.2.11 such as a 
movement of the film while transferring of a movement of the film while developing. If either 
one of these mistakes were made, the bands around the 10kDa marker are likely to be the same 
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ISG15 band just lower down. Alternatively, the cell lysate may have started to degrade. Despite 
snap-freezing in liquid nitrogen and storing at -80°C overnight, the lysate may have become 
unstable and the smaller protein may no longer be present.  
In order to comprehensively determine if there was a genomic deletion or alteration present, 
all of the sample clones were sent for sequencing. Due to a contamination of the DNA of the 
clones, it was not possible to sequence the DNA. As there were time constraints at the end of 
the project it was not possible to extract new DNA from the clones. As the sequencing results 
could neither deny or confirm the alteration of the genome it is still unknown as to whether a 
deletion is present.  
Although it has not been confirmed, the results from these experiment suggest that the genome 
has been altered. The same CRISPR plasmid for Exon 2 was used in both experiments yet quite 
different results were seen. The only other alteration in experimental procedure was the use of 
electroporation instead of attractene to transfect the plasmid. This may not be the reason behind 
the differences in the results yet it is possible that electroporation increases the odds of a more 
effective transfection.  
 
4.3 Single Chain Purification of ISG15: 
The single chain purification protocol A was based on the protocol designed by Mariana 
Cristina De Sa Cardoso Dos Santos during her MRes in the lab of Ted Hupp. Throughout the 
protocol, samples were taken at every step in order to determine where and when the single 
chain has been induced before starting the purification step. The samples taken from protocol 
A can be seen in the gel Figure 3.1.1. All of the lanes contain bands, yet the bands in lanes 
before induction are more prominent and more frequent than the bands in the lanes after 
induction. If the single chain is present, it will likely be in the after induction lanes and a clear 
band should be seen around the 36kDa mark. No bands of this size can be seen in any of the 
lanes. In fact, most of the protein after induction seems to be degraded.  
Despite this, an attempt to purify any single chain present was carried out. Figure 3.3.2 and 
Figure 3.3.3 show the commassie stained gels of the elutes and the washes. From Figure 3.3.3 
we can that some of the protein has remained in the flow-through and in wash 1. Whether the 
single chain is in this remains unclear. As no protein was seen in the elutes it is possible that 
the single chain was pulled out in the flow-through and in the first wash. It is also possible that 
there was no protein present as an exact band was not seen in the bacterial culture gel. 
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Based on these observations it was decided to repeat the experiment and alter the protocol.  
In Protocol A the plasmid was left to induce overnight at 30°C. From the gel in Figure 3.3.1 
we can see that very little protein is present after the long induction time, especially any smaller 
proteins. Based on these observations it was concluded that the long incubation time was a 
major problem in the protocol and so in Protocol B the incubation time was cut to 6 hours. 
Protocol C was carried out at the same time with an incubation time of just three hours. From 
the gel in Figure 3.3.4, we can see that very little protein is present in the flow-through and 
wash lanes. This could be a positive sign as it means the single chain protein has not been 
eluted through the washes. However, the lack of protein in the washes and flow through 
coupled with the lack of elutes seen in Figure 3.3.5, it suggests that the single chain has not 
been induced. No clear bands can be seen around the 36kDa mark in any if the lanes in Protocol 
B, either in the elutes or washes and flow through.  
In the Protocol C lanes in Figure 3.3.4, multiple distinct bands can be seen in the flow-through 
and wash 1 lanes. A band can be seen in these lanes around the 36kDa marker indicating that 
there is a strong possibility of the single chain being present. Due to the fact the bands can be 
seen in the elute lanes in Figure 3.3.5, the entirety of the single chain was not lost in the flow 
through and washes. The bands in Elute 1, Elute 2 and Elute 3 are distinctive and around the 
36kDa marker. The faintness of the bands compared to the BSA lanes suggests the 
concentration is very low. Protocol C, however, has worked.  
As the plasmid is quite small, a lower incubation time seems to work more efficiently. The 
longer the plasmid is incubated for the more protein is degraded. Larger proteins can withstand 
the incubation period better than the smaller more soluble proteins. It was necessary to 
understand this in order to move forward with the experiment. 
Before the affinity of the antibodies can be tested, their concentrations must be determined. As 
the concentrations of the single chains are too low to be determined using a Bradford reagent 
test, other less accurate methods must be pursued. 
In Figure 3.3.7 the intensity levels of the BSA standard bands from the gel in Figure 3.3.6 were 
mapped on an excel graph. Using the equation of the graph, the concentration of the Elute 1 
was deemed to be negligible. The concentration of Elute 2 was also too low to be accurately 
determined using this method. The concentration of Elute 3 was calculated to be roughly 0.012.   
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This method is not entirely accurate however. The BSA standards are approximately three 
times the size of the single chain protein and therefore absorb three times as much loading dye, 
increasing the intensity level by a factor of three. Based on this the concentration of elute 1 
would be approximately 0.018 and the concentration of elute 2 is likely 0.036.  
As described in Figure 3.3.8 a variety of concentrations were used as the primary antibody. 
These concentrations were calculated based on the much lower original single chain 
concentrations. The results of the ELISA were plotted on an Excel graph as shown in Figure 
3.3.9. from this graph we can see that the single chain has a very high affinity for pure ISG15, 
even in low concentrations. No protein was added to two lanes as a control.  
To further test the ability of the single-chain, a dot blot was performed. A dot blot is a simplified 
version of the western blot which eliminates the need for gel electrophoresis. The molecules 
are not separated in this procedure but since only a pure protein was loaded this was not 
necessary. In Image A Figure 3.3.10, although the blot is messy, dot can be seen in squares 
with concentrations of 1ng, 10ng and 100ng. Although the other two squares had higher 
concentrations of 200ng and 500ng, no dots could be seen. The blot in Image A Figure 3.3.10 
was so dirty that it is possible the dots in the 200ng square and 500ng square were obstructed. 
The blot was washed again thoroughly with PBST in an attempt to clean the blot further, despite 
having performed multiple washes before the addition of ECL. When the blot was washed 
again and developed, a dot was only seen in the 10 ng square. The washing has likely washed 
off the protein. The antibody is likely very sticky as the blot was quite dirty despite multiple 
washes. A lower concentration of primary antibody would probably have given a cleaner blot. 
In this blot we also see failure of the single chain to bind to higher concentrations of proteins. 
While this may be just an experimental mistake, it may also indicate an inability of the single 
chain to bind when saturated with protein.  
The ELISA protocol and the dot blot test the ability of the single chain to bind to the pure form 
of ISG15. When a protein is run on an SDS-PAGE gel however the protein becomes denatured 
and binding site of the protein may be altered. To investigate if this is the case and to identify 
the amount of loaded protein necessary for the single chain binding, a titration of pure ISG15 
concentrations were loaded. The singe chain was used as the primary antibody as at 2mg/ml. 
This concentration was calculated using the more accurate, higher concentration of the single 
chain elute 3. From the gel in Figure 3.3.11 we can see that the single chain has the ability to 
bind to even very low concentrations of protein. No clear bands can be seen in the lanes with 
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higher concentrations of protein. This anomaly is likely due to an error in transferring. Despite 
the denaturing of the ISG15 on the gel, the single chain antibody was still capable of efficiently 
binding to the protein.  
Single Chain purification is a highly effective method of creating a specific antibody for a 
certain gene. By optimising the process for inducing and purifying the single chain, it will be 
possible to recreate this experiment and produce large quantities of a single chain antibody 






















Future Directions:  
During the course of these experiments a number of positive results were obtained. These 
results however opened the door for a wide variety of future experiments to be carried out. 
Identifying the proteins involved in ISGylation would greatly increase our understanding of 
the roles of ISG15. As it known how to induce ISGylation, samples could be sent for mass 
spectrometry and the proteins involved could be quantified.  
If time constraints were not an issue, the DNA of the CRISPR clones would be extracted from 
fresh samples and they would be resent for sequencing in order to identify any genomic 
alterations. If the sequencing results showed positive CRISPR clones, a multitude of 
experiments could be carried out. These would include treating the clones with Camptothecin 
as literature has stated that cells which lack ISG15 show decreased sensitivity to CPTs. This 
could be compared to the wild type cell lines which should have a higher sensitivity.  
The single chain purification elutes could be further analysed to determine their 
concentrations. Having the correct concentrations would increase the accuracy of the 
experiments and their results and would allow for a more in depth interpretation of their 
affinity. The single chain could then be used for any experiments which require an ISG15 
antibody. The protocol could also be altered and tested to try and further optimise the plasmid 
induction. Protocol C, the only working protocol, was run at 37°C which is quite a high 
temperature for plasmid induction. It was thought that the shorter incubation time required a 
higher temperature however inducing the plasmid at the lower temperature, even for the 
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